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ABSTRACT OF THE DISSERTATION 
24-Hours of Heart Health: An Analysis of Sleep Duration and Cardiovascular Disease in the 
OPACH Cohort 
by 
Kelsie M. Full 
Doctor of Philosophy in Public Health (Health Behavior) 
University of California San Diego, 2018 
San Diego State University, 2018 
Professor Jacqueline Kerr, Chair 
 Background: Cardiovascular Disease (CVD) is the most prevalent chronic disease in the 
aging population. Older women are at greatest risk for CVD, higher than their male counterparts. 
Disparities in the incidence and prevalence of CVD and CVD risk factors in older women, 
suggest that current prevention strategies are not effective for these populations. Research shows 
that post-menopausal women experience difficulty adapting to age-related changes in sleep. 
Considering 1/3 of the day is spent sleeping, sleep duration is a potential modifiable CVD 
lifestyle risk factor worthy of greater exploration. Aging research to date has included a focus on 
the cardiometabolic associations of sleep duration, including large-scale epidemiological studies 
xx 
and meta-analyses concluding that inadequate sleep duration and poor sleep quality are 
associated with increased development, progression, and severity of CVD and CVD 
comorbidities. Research, however, has mostly employed self-reported sleep measures, focused 
on Caucasian populations and has not considered sleep as part of the 24 hour day. There is a 
need for research to examine the relationship between sleep duration and CVD risk in an older 
population of women, and to determine if insufficient sleep duration, short or long, is a CVD risk 
factor worthy of further examination.  
 Methods: This dissertation leverages data from the unique “Objective Physical Activity 
and Cardiovascular Health” (OPACH) study among 6489 women, ages 63-99, recruited from 
a Women’s Health Initiative cohort. Women wore ActiGraph GT3X+ accelerometers on the 
hip for 24 hours per day and completed a daily sleep log over a 7-day period. In addition to 
accelerometer-measured 24-hour activity data, the OPACH study includes measures of 
physical functioning, lifestyle questionnaires, and clinical biomarkers. Participants were 
contacted yearly to provide updated medical history including self-report of CVD events 
with follow-up up to 5 years. Sleep data were scored according to a standard protocol using 
sleep logs. Chapter 1 assessed if sleep duration, measured with accelerometers, is associated with 
numerous cardiometabolic markers, including measures of insulin resistance, inflammation and 
body composition in older women. Chapter 2 was an examination of the relationship between 
sleep duration and the Reynolds Risk Score, a clinically relevant composite CVD risk score. In 
Chapter 3, the relationship between cardiovascular events over 3-5 years of follow-up and self-
reported sleep duration and accelerometer-measured sleep duration was examined. 
 Results: Chapter 1 found significant associations between sleep duration and markers of 
cardiometabolic health. Several of these relationships suggested the relationship was u-shaped, 
xxi 
with short and long sleep associated with higher cardiometabolic values. Chapter 2 further 
explored this relationship and demonstrated that sleep duration is non-linearly associated with 
10-year estimated CVD risk among older women. In Chapter 3, there was no significant increase 
in CVD risk for short or long sleep durations over the 5-year period, measured by self-report or 
accelerometer.   
 Discussion: The results of this analysis demonstrate sleep duration is related to markers 
of cardiometabolic health and intermediate CVD risk, but that sleep duration does not 
independently predict incident CVD. These findings may be explained by the interdependence of 
24-hour activities, including sleep duration, and their relationship to cardiometabolic health. 
While results do not support sleep duration as a risk factor for CVD, they do support sleep 
duration as a lifestyle behavior worth targeting for cardiometabolic risk reduction in older 
women. To better understand how sleep relates to cardiometabolic health, we must better 
understand the interdependence and interrelationships of activities throughout the 24-hour day. 
 
 1 
INTRODUCTION 
 The aging population in the United States (US) is in a period of rapid growth. By 2050, 
the population over the age of 65 will surpass 80 million, doubling in size from 2010.1  Not only 
are more adults entering the demographic group defined as older adult, but within this 
population, older adults are also living longer.1 In line with the growing older adult population, 
there has been an increase in the focus on the promotion of healthy aging and aging research. 
Current aging research is focused on understanding the public health burden of chronic diseases, 
the changing definition of disability, and the use of medical care associated with the growing 
healthcare needs of this population. It is estimated that over 80% of the older adult population 
have at least one chronic disease, and almost 30% of these have two chronic conditions. With 
each chronic condition the costs associated with medication use and medical care increases. In 
the next decade, research focused on reducing the prevalence and burden of chronic conditions in 
the aging population through lifestyle behavior modification is critical.2,3 
 Cardiovascular Disease (CVD) is the most prevalent chronic disease in the aging 
population.2 According to the American Heart Association, CVD is a disease of the heart or 
blood vessels, including heart attack, stroke, arrhythmia, and heart valve problems.4 In the US, 
CVD is the leading cause of death, accounting for 1 in 4 deaths; approximately 10,000 deaths 
annually.5 Over the course of the last 50 years, CVD mortality rates in the US have decreased 
across every population subgroup.6 Despite the overall reduction in deaths, CVD is still a 
significant public health problem. Advances in CVD prevention have reduced the number of 
CVD deaths overall, however in the last decade CVD deaths in females have exceeded those in 
males.7,8 For women, CVD is responsible for more deaths than all forms of cancer combined.9 
Older women over the age of 80 years are at greatest risk for CVD, with higher incidence of 
 2 
CVD events than their male counterparts.5 Rates of CVD prevalence and mortality differ across 
racial-ethnic subgroups of women. African American women have higher rates of CVD, CVD 
mortality, and CVD risk than any other racial/ethnic subgroup.8-10 In the US, nearly half of 
African American women are currently living with CVD.8 Much less is known about the rates of 
CVD in Hispanic/Latino, Asian American, and American Indian women.11 Overall, The 
American Heart Association estimates that more than one in three US women has some form of 
CVD, and an additional 90% of women are currently living with one or more risk factors.9 
 There are a number of modifiable risk factors that increase an individual’s risk for 
developing CVD including: obesity, elevated total cholesterol, reduced HDL cholesterol, 
diabetes, hypertension, and elevated high-sensitivity C-reactive protein (CRP).9 Additionally, 
lifestyle behaviors such as smoking, poor diet, lack of physical activity (PA), and sedentary 
behavior (SB) have been identified and shown to increase a women’s risk of developing CVD 
and developing CVD risk factors.5,7,9 Epidemiologic studies predict that the prevalence of these 
risk factors will only continue to increase for women in the US population.12,13 As the prevalence 
of CVD and CVD risk factors increase in the US population, it is apparent that more research is 
needed to identify risk factors that can be modified and targeted for lifestyle interventions.  
 Poor or insufficient sleep is a potential CVD lifestyle risk factor worthy of greater 
exploration. Hours spent sleeping account for more than 30% of daily behavior.12 Recently, sleep 
has gained public health attention as a modifiable behavior related to various chronic health 
conditions. Research has included a focus on the cardiometabolic effects of poor or insufficient 
sleep, including a number of cross-sectional and prospective studies demonstrating that self-
reported sleep duration is a predictor of incident cardiometabolic conditions such as: type 2 
diabetes, hypertension, and obesity (Table I.1).13–33 In addition to the large number of studies 
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examining the association between sleep duration and CVD risk factors, longitudinal studies 
have found that self-reported sleep duration was independently associated with an increased risk 
of CVD events and CVD mortality (Table I.2).34–43 Meta-analyses of the existing research have 
concluded that inadequate sleep duration and poor sleep quality are associated with increased 
development, progression, and severity of CVD and CVD comorbidities.10  
 Specifically for older adults, there is even greater evidence supporting sleep duration as a 
risk factor for CVD. As risk of CVD increases with age, so does the risk of experiencing 
inadequate sleep durations and poor sleep quality. Over half of older adults in the US regularly 
report experiencing disturbed sleep.44 Age-related changes in sleep include shorter or longer total 
sleep time (TST), increased frequency of awakenings, difficulty maintaining sleep, decreased 
sleep efficiency, and changes to sleep architecture.44–48 While these age-related changes in sleep 
are common among older adults, evidence suggests that post-menopausal women experience 
more difficulty adapting to these changes. Older women are more likely to report poor sleep 
quality, sleep disturbances, and nocturnal awakenings than their male counterparts.44,46,48 If sleep 
duration is a risk factor for the development and progression of CVD, the large proportion of 
older adult women who regularly experience short or long sleep are at risk and pose a significant 
public health concern.49 There is a need for research to examine the relationship between sleep 
duration and CVD risk in an older population of women, and to determine if insufficient sleep 
duration, above and beyond physical inactivity, is a CVD risk factor worthy of further 
examination.  
 Besides pharmacological intervention, cardiovascular prevention strategies for women 
focus on the reduction of CVD risk through the promotion of a healthy lifestyle. Current lifestyle 
interventions have primarily focused on smoking cessation, increasing daily minutes of PA and 
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maintaining a well-balanced diet.5,50 Objectively measured PA, using accelerometers, has shown 
to independently have beneficial associations with cardiometabolic health and be protective 
against incident CVD.51,52 For women, increases in daily minutes of PA decrease CVD risk,53 
however the results of many PA interventions have shown only moderate increases in PA among 
women.54  For older women, meeting PA intervention targets is even more difficult to achieve. In 
fact, estimates show that <10% of participants adhere to prescribed lifestyle treatment and 
intervention guidelines.50 The disparities in the high incidence and prevalence of CVD and CVD 
risk factors specifically in women and subgroups of women, suggest that current prevention 
strategies are not effective for these populations. To improve upon current approaches to CVD 
prevention for women, the AHA has funded a Strategically Focused Research Network of 5 
centers who will receive $15 million dollars and are committed to advancing research of CVD 
prevention in women. One of the SFRN centers is focused on exploring SB as a CVD lifestyle 
intervention target. SB interventions may hold more promise for women, when PA targets are 
not achievable. Laboratory studies have shown breaks in sedentary time, even more than PA 
bouts, were related to meaningful decreases in biomarker-measured CVD risk.55,56 A population 
based study demonstrated that a 1-2 hour reduction in sedentary time was related to substantial 
reductions in CVD risk.57 New research studies targeting reductions in daily SB have achieved 
large reductions in sitting time, including in older adults, and have shown the independent health 
impacts of SB while adjusting for PA.58 The potential success of the SB interventions not only 
demonstrates the need to explore novel lifestyle risk factors, beyond PA, that may be more 
achievable and more effective in decreasing CVD risk among women, but also that we must 
consider that behaviors do not occur in isolation and are a part of the finite 24-hour day. The 
majority of current CVD lifestyle interventions have targeted changing one behavior without 
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considering the impact this will have on the other behaviors that make up the 24-hour day, 
including sleep.  
 Thurs far, sleep intervention studies has been limited in number, size, and scope and have 
not been designed to directly target CVD prevention in women. Clinical experimental studies 
focused on altering sleep duration have been primarily concerned with the impact of restricting 
sleep duration on energy intake (diet), energy expenditure, or on markers of insulin resistance 
and inflammation.59 These studies are more focused on the mechanistic pathways through which 
sleep may be related to weight gain, metabolism, and markers of cardiovascular health and 
therefore have been small in sample size, limited in generalizability, and short-term in length. 
There is a need for research designed to assess the longer-term impact of sleep duration 
interventions, with the inclusion of women, older adults, and other underrepresented population 
subgroups.59 Further, more research is needed to determine if sleep duration, independent of 
other 24-hour activity, should be considered an intervention target for CVD lifestyle 
interventions for women. 
 Overall the aim of this thesis is to assess if sleep duration is independently associated 
with cardiometabolic health and if insufficient sleep duration is a risk factor that contributes to 
the development of CVD in older women. This thesis will leverage the rich and unique OPACH 
study dataset. “Objective Physical Activity and Cardiovascular Health” (OPACH) was a 
funded ancillary study to the Women’s Health Initiative (WHI) Long Life Study. The NHLBI-
Long Life Study was an extension study of the WHI-observational cohort and was conducted 
between 2012-2013. Women were recruited from 40 clinical centers across the US. The study 
included 7875 women between the ages of 63-99 from previous WHI cohorts. With the purpose 
of having a race/ethnicity diverse study sample, the Long Life Study purposefully oversampled 
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to compile a cohort that was 48% white, 35% African-American, and 17% Hispanic. The 
objective of the OPACH study was to examine CVD and accelerometer-measured PA in older 
adult women. The consented OPACH sample included 7048 women. While the primary aim of 
the OPACH study was focused solely on PA, 24-hour activity data was collected. In addition to 
accelerometer-measured 24-hour activity data, the OPACH study includes measures of 
physical functioning, lifestyle questionnaires, and clinical biomarkers. Participants were 
contacted yearly to provide updated medical history including self-report of CVD events 
with follow-up up to 5 years.  
 This thesis aims to build upon the existing research on sleep duration and CVD risk in 
women, and to further contribute to the scientific evidence by addressing some of the gaps in the 
current literature. Figure I.1 depicts the aims of three chapters and the relationships assessed in 
this thesis. 
 Chapter 1 contributes to the existing research on sleep duration and CVD risk by 
providing an in-depth analysis of the relationship between accelerometer measured sleep 
duration and markers of cardiometabolic health. The aim of chapter 1 is to assess if sleep 
duration, measured with accelerometers, is associated with numerous cardiometabolic markers, 
including measures of insulin resistance, inflammation, body composition, and cardiovascular 
health in older women. As outlined in Table I.1, the majority of research examining the 
relationship between sleep duration and cardiometabolic health has used self-reported measures 
of sleep duration. Further, the relationship between sleep duration and CVD risk factors have not 
been sufficiently examined in racial-ethnically diverse samples of older women. This chapter 
provides a significant contribution by using accelerometer-measured sleep in a diverse cohort of 
older women to examine how sleep duration is related to cardiometabolic health. Additionally, in 
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this analysis novel isotemporal modeling techniques are used to explore the interrelationship of 
sleep duration with the other 24-hour day activities that are related to cardiometabolic health, 
including PA and SB. These analyses will contribute significantly to understanding not only how 
sleep duration, but 24-hour activity is related to cardiometabolic health in older women and will 
be one of the first analyses to do so using rigorously processed 24-hour accelerometer data with 
accelerometer measured sleep duration. 
 Building on the assessment of sleep duration and markers of cardiometabolic health, 
Chapter 2 is an examination of the relationship between sleep duration and a clinically relevant 
CVD risk score, the Reynolds Risk Score (RRS); used clinically to predict 10-year risk of 
CVD.60 Previously the relationship between self-reported sleep duration and individual CVD risk 
factors has been examined, with reviews and meta-analyses compiling data to draw conclusions 
about overall cardiometabolic risk.10,35,61,62 While examining CVD risk factors individually may 
explain the relationship between sleep and cardiometabolic health, they may not explain the 
relationship between sleep and overall CVD risk. Further, in the clinical setting, composite risk 
factor scores are valuable to predict overall CVD risk and to help decide need for further testing 
(e.g. stress testing, coronary calcium measurements). This chapter is one of the first analyses to 
include accelerometer measured sleep duration and a composite CVD risk factor score to 
examine sleep duration and estimated CVD risk in older women.  
 In Chapter 3, the relationship between cardiovascular events over 3-5 years of follow-up 
and two different methods to estimate sleep duration is examined. This chapter includes one of 
the first prospective studies to examine the association between accelerometer-measured sleep 
duration and incident CVD. Further, previous studies have assessed self-reported sleep duration 
and CVD events. This analysis includes both self-reported sleep duration and accelerometer-
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measured sleep duration in the same diverse cohort of older women and is able to draw 
comparisons between the two measures. Chapter 3 will fill an existing gap in the literature as one 
of the first studies to assess the relationship between sleep duration and incident CVD using an 
objective measure of sleep duration, as well as providing insight on how the relationship between 
sleep duration and CVD risk differs by different methods to estimate sleep duration. This study 
will provide much needed evidence on the relationship between sleep duration and incident CVD 
in older women. 
 There are many limitations in the existing scientific evidence of the link between sleep 
duration and cardiovascular health. This thesis aims to address these gaps to advance our 
understanding of the role that sleep duration plays in CVD development in older women. First, 
many of  the existing epidemiologic studies have relied on self-reported sleep duration from 1 or 
2 survey items that ask a question similar to: “How many hours of sleep do you usually get a 
night?”14,61,63 A previous validation study comparing self-reported sleep duration to wrist 
actigraphy in a sample of over 600 adults indicated self-report is usually an overestimate of sleep 
duration, is only moderately correlated to objectively measured sleep duration (r=0.47), and has a 
systematic bias across social-demographic characteristics.63,64 Studies that have used objective 
measures of sleep duration have found different results in the associations between sleep 
duration and cardiometabolic risk factors, with some studies showing no significant 
associations.20,26,28,30,32  Additionally, previous study samples primarily consisted of middle-aged 
non-Hispanic white adults. While CVD incidence is higher in older women, and African 
American and Non-white Hispanic populations,5 most published studies on sleep and CVD risk 
have not adequately included women with broad representation from these groups.10,59  This is a 
concern as evidence suggests that sleep duration and quality differs across age groups and 
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racial/ethnic groups.47,65 According to the American Heart Association, inclusion of these 
understudied populations, including aging women and African American and Non-white 
Hispanic women, and the objective assessment of sleep, should be high priorities for future 
research.59 Lastly, based on the growing evidence that demonstrates the interrelationships of 
daily activities, it is important we move beyond the paradigm of considering activities in 
isolation. To better understand the relationship between sleep duration and CVD, we must also 
account for how daily PA may influence this relationship. This thesis will leverage the 24-hour 
activity data to account for daily PA and SB in the relationship between sleep duration and CVD. 
This additional step has rarely been included in previous sleep and cardiovascular health studies. 
 In summary the purpose of this dissertation is to build upon the existing research on sleep 
and cardiovascular health in older women. By using accelerometer-measured sleep duration 
collected in a large and diverse cohort of older women, and through the application of analytic 
approaches that take into consideration how sleep is part of the 24-hour day, this dissertation is a 
much needed contribution to existing scientific evidence. In this dissertation, accelerometer-
measured sleep duration has been examined in relationship to markers of cardiometabolic health, 
10-year estimated risk of CVD, and CVD events. The results of this dissertation will fill gaps in 
the existing evidence base and will inform lifestyle intervention strategies for CVD prevention. 
Further, as the popularity of 24-hour data collection increases with the advancement of research 
activity measurement devices, considering the contribution of sleep to the 24-hour day is not 
only relevant, but imperative to improving how we approach CVD prevention. The growing 
older adult population warrants renewed focus on feasible and effective CVD prevention 
strategies for older adult women. The results of this dissertation will provide an extensive 
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analysis of the role sleep duration plays in cardiometabolic health and CVD risk and will provide 
insights for future lifestyle CVD prevention strategies for older women. 
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Figure I.1: Conceptual model for 24-hour heart health dissertation 
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CHAPTER 1 
Modeling the Cardiometabolic Benefits of Sleep in Older Women: 
Exploring the 24-Hour Day 
ABSTRACT 
 Background: Activities throughout the 24-hour day, including sleep, sedentary behavior 
(SB), and physical activity (PA) have been associated with cardiometabolic health. Few studies 
have examined the relationship between accelerometer-measured 24-hour activity and 
cardiometabolic risk factors. Sleep extension may be a feasible cardiovascular intervention 
strategy; however, more research is needed to understand of what activity from within the 24 
hour day additional sleep should displace.  
 Methods: Women from the Objective Physical Activity and Cardiovascular Health Study 
(N=3329; mean age 79.05 years) wore ActiGraph GT3X+ accelerometers on the hip for 24 hours 
and completed a daily sleep log. Sleep data were scored according to a standard protocol using 
the sleep logs. Adjusted regression models estimated the relationship between sleep duration and 
cardiometabolic markers. Stratified by sleep duration (<8 hours, >8 hours), isotemporal models 
were run across to estimate the association with  cardiometabolic markers of reallocating 
daytime activity time (SB, light PA (LIPA), moderate to vigorous (MVPA)) to or from sleep. 
 Results: After adjustment, sleep duration was significantly related to insulin, C-reactie 
protein, insulin resistance, glucose, total cholesterol, triglycerides, waist circumference, and 10-
year estimated CVD risk. For short sleepers, reallocating one standard deviation (33 
minutes/day) of MVPA to sleep was detrimental across all cardiometabolic markers. Similar 
detrimental associations were observed when LIPA (74 minutes/day) was reallocated to sleep. 
Reallocating one standard deviation of SB (91 minutes/day) to sleep had small beneficial 
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associations with some of the cardiometabolic markers. In long sleepers, reallocating time from 
sleep to MVPA or LIPA had beneficial associations. 
 Conclusions: In older women, there was a significant relationship between sleep duration 
and cardiometabolic risk factors. Results from isotemporal models indicate possible risks and 
benefits of reallocating time to or from sleep to lower cardiometabolic risk, but results must be 
confirmed in randomized clinical trials.  
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INTRODUCTION 
 Throughout the 24-hour day, time is spent in activities that can be distinctly categorized 
as sleep, sedentary behavior, or physical activity (light physical activity and moderate to 
vigorous physical activity). Individually, these 24-hour activities are linked to cardiometabolic 
health. Objectively measured physical activity (PA), both moderate to vigorous (MVPA) and 
light intensity (LIPA) have been shown to have beneficial associations with cardiometabolic 
health including reduced risks of incident cardiovascular disease (CVD).1,2 Objectively measured 
sedentary behavior (SB) has detrimental associations with markers of cardiometabolic health and 
has been associated with increased risk of incident CVD, even after adjusting for PA.3–6 Self-
reported short sleep durations (<7 hours) predict incident cardiometabolic conditions such as: 
type 2 diabetes, obesity, and cardiovascular events.7–12 Only a few cross-sectional studies have 
used wearable sensors to examine associations between objectively measured sleep duration, 
both short and long, and modifiable cardiometabolic risk factors, including cardiovascular 
biomarkers (such as glucose and C-reactive protein), systolic blood pressure, and obesity.13–17  
 Despite the growing research on the relationship between sleep duration and 
cardiometabolic health, epidemiologic studies show that over 30% of Americans are not getting 
the recommended 8 hours of sleep  per night.18 For older women, reports of poor or disturbed 
sleep are higher than for men.19 Age-related changes in sleep lead to more frequent reports of 
poor sleep quality, restless sleep, and more nocturnal awakenings.20–23 Focusing on extending or 
decreasing sleep time for cardiometabolic risk reduction may be an interventional strategy worth 
exploring for aging women. Recent evidence suggests that sleep extension interventions may be 
a feasible strategy to reducing CVD risk.18,24  
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 The high incidence and prevalence of CVD among older women in the United States 
suggest that current cardiovascular prevention strategies may not be completely effective for 
aging women. Many existing lifestyle interventions focus on increasing daily PA. However, it is 
estimated that only 10-30% of older adults currently meet PA guidelines of 30 minutes of daily 
MVPA.25,26 Sleep extension interventions may be a more feasible alternative to PA interventions 
particularly in older populations where PA may be difficult to achieve due to health or 
environmental barriers. Additionally, new research on daily SB reduction holds promise as large 
reductions in sitting time have been achieved.27 As clinical recommendations and sleep research 
support increasing sleep time, more research is needed to understand from where in the 24-hour 
day that time should come. Would it be beneficial if participants reduce sitting time to increase 
sleep time? Further, it is not clear whether it is more beneficial to increase a behavior like PA, or 
if it also results in less sleep time.  
 Recently, researchers have used Isotemporal Substitution Modeling28 to estimate the 
change in cardiometabolic risk if a fixed amount of time spent in one activity is shifted to 
another activity. Several of these studies have demonstrated that the way time is allocated to 
daily activities is significantly related to cardiometabolic health.29–31 Previous isotemporal 
analyses have focused on daytime activity and most have not included sleep in their analyses. 
The isotemporal studies that did include sleep relied solely on self-reported sleep measures.28–32  
 The primary aim of this study was to use 24-hour accelerometry data to: (1) examine the 
associations between objectively measured sleep duration and markers of cardiometabolic health; 
and (2) construct isotemporal substitution models to assess the cardiometabolic associations of 
redistributing time to or from sleep, when it is shifted to or from another activity. This study 
differs from the isotemporal approaches previously taken, by including objectively measured 
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sleep duration and focusing specifically on reallocating time to or from sleep duration. This 
modeling will answer the questions: What is the benefit on cardiometabolic risk of increasing 
sleep duration, in short sleepers, if time spent in SB is decreased? Or what is the benefit of 
decreasing sleep duration, in long sleepers, if time spent in LIPA or MVPA is increased? This 
study will provide a better understanding of how 24-hour activity is related to cardiometabolic 
health and may highlight opportunities to develop more feasible cardiovascular lifestyle 
interventions which could be tailored to older adults’ capacity for behavior change. 
METHODS 
Study Sample 
 Our study population included older women enrolled in the Objective Physical Activity 
and Cardiovascular Health (OPACH) study, an ancillary study to the Women’s Health Initiative 
Long Life Study aimed at examining the relationship between accelerometer-measured physical 
activity and incidence of CVD in older women (ages 63-99 years). More detailed information on 
the OPACH study objectives, recruitment, and methodology are published.33 Participants were 
consented for participation in the OPACH study (N=7048) between 2012-2013 and in-home 
visits were conducted to obtain fasting blood draws, health and lifestyle questionnaires, 
anthropometric measurements, and blood pressure readings. At the home visit, participants 
received a GT3x accelerometer, instructed to wear the device on their waist for 24 hours per day, 
and asked to complete a daily sleep log over a 7-day period. Of the consented OPACH 
participants, 6,489 women returned their device and provided at least one day of accelerometer 
data; 6,114 of these women also completed sleep logs for at least one day. To be eligible for the 
present study, women had at least two 24-hour periods of valid accelerometer data, a completed 
sleep log, and fasting CVD biomarker results (Figure 1.1).  
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Objective 24-Hour Activity 
 24-hour activity was assessed with a hip-worn triaxial accelerometer (Actigraph GT3X+; 
Pensacola, FL). The ActiGraph device, worn on the hip, has been validated for physical activity, 
sedentary behavior and sleep duration estimates.34,35 Data were recorded in 1-second epochs at 
30 Hertz. After the device was returned, raw data were processed using ActiLife version 6.11 
software, separately for sleep duration and the daytime activity variables.  
Sleep Duration 
 The sleep duration data were processed using the raw data condensed to 60 second 
Agilegraph Data File (AGD) with the low frequency extension filter applied. AGD files were 
scored using a standard protocol. A trained member of the research team identified the primary 
sleep window using the participant sleep logs and a visual review of the data for each night the 
participant wore the device. This procedure is aligned with the Society of Behavioral Sleep 
Medicine actigraphy methods guidelines and draws from a protocol shown to have high 
interrater reliability.36,37 The validated Cole-Kripke algorithm38 was applied and classified the 
sleep window, minute by minute, as sleep or wake time.  Estimates of nightly sleep duration 
were derived from the summing of epochs classified as sleep (minutes/night) during the defined 
in-bed period.  
Physical Activity and Sedentary Behavior 
 PA data were processed as previously described in detail.33 Age-appropriate PA-intensity 
cut points were used to classify PA intensity levels,39 including: light physical activity 
(LIPA;19–518 counts/15 s) and moderate-to-vigorous intensity (MVPA; ≥519). SB was defined 
as less than 19 counts/15 second period. In bed time that was not classified as sleep by the sleep-
wake algorithm was defined as SB. 
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Markers of Cardiometabolic Health 
 Resting blood pressure (BP) was measured after a 5-minute rest period using an aneroid 
sphygmomanometer and cuff size based on measured arm circumference. The average of two BP 
readings was recorded. Participant height (cm) and weight (kg) were assessed by trained staff 
using a portable scale and stadiometer. Participants’ body mass index (BMI)(kg/m2) was 
calculated with the height and weight obtained at the LLS study visit. Fasting blood samples 
were sent to the University of Minnesota Fairview Advanced Research and Diagnostic 
Laboratory (ARDL) for cardiometabolic biomarker testing as previously described.40 The 
following markers of cardiometabolic health were included in these analyses: fasting insulin, C-
reactive protein (CRP), homeostatic model assessment of insulin resistance (HOMA-IR), fasting 
glucose, HDL cholesterol, total cholesterol, triglycerides, systolic blood pressure, waist 
circumference, BMI, and Reynolds Risk Score (RRS),41 a composite index that estimates 10-year 
CVD risk.    
Covariates 
 Participant demographic information, education, smoking, self-rated heath, self-reported 
sleep disturbances, and history of chronic conditions were ascertained with the LLS and WHI 
lifestyle survey and medical history questionnaires. Self-rated health was derived from 1-item 
from the WHI lifestyle questionnaire: “In general would you say your health is…”. Response 
options ranged from “excellent” to “poor”. The WHI Insomnia Rating Scale (WHIIRS) was used 
to assess self-reported sleep disturbances.42  The five item scores (0-4) are summed to create a 
scale score ranging from 0-20. A higher WHIIRS score is reflective of greater presence of sleep 
disturbances and has been shown to predict CVD.43 Self-reported chronic conditions were 
collected in the baseline LLS survey and were used to create a comorbidity index score. The 
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index included self-reported history of chronic obstructive pulmonary disease (COPD), 
osteoarthritis, cerebrovascular disease, cancer, cognitive impairment, and hip fractures. The 
number of conditions was summed to create a comorbidity index score (0-6). Participants were 
categorized as having no comorbid conditions (0), 1-2 conditions (1), or more than 2 conditions 
(2).   
Statistical Analysis 
 Average daily minutes of sleep, PA, and SB were included in a series of regression 
models to assess the associations with markers of cardiometabolic health. Prior to analyses, all 
cardiometabolic marker variables were log transformed. All of the activity variables were 
adjusted for device wear time using the residuals method44 to account for variation in wear time 
across individuals that may impact estimates of 24-hour activity categories. Daily activity 
variables were summed to create a 24-hour total wear time variable. Models included adjustment 
for age, race/ethnicity, education, sleep disturbances, self-rated health, smoking status and an 
index of comorbid conditions.  
Single Variable Models 
 Single-variable linear regression models for each marker of cardiometabolic health and 
each activity were performed and estimated mean values for each cardiometabolic marker were 
compared according to sleep durations of 6 hours, 8 hours, and 10 hours, adjusting for 
confounders, but not for the other types of activity. As one of the aims of the current analyses 
was to examine the effect of reallocation of time to or from sleep duration, the primary focus was 
on the independent associations of sleep duration with cardiometabolic markers as the first step. 
The single variable models for MVPA, LIPA, and SB were also performed adjusting for 
covariates and confounders. Evidence demonstrates that the relationship between sleep duration 
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and cardiometabolic biomarkers may be U-shaped, with both short and long durations 
significantly associated with various cardiometabolic biomarkers. A quadratic term was included 
in the single variable models to explore the possible U-shape in the relationships. When the 
quadratic term was not significant, it was removed, and the model was rerun with only a linear 
term for sleep duration to examine the possible linear association.  
 When significant associations were observed in the single variable sleep models, 
isotemporal substitution models were performed across the stratified sample (<8 hours, ≥8 hours) 
to test the reallocation of time to sleep for short sleepers and from sleep for long sleepers. 
Isotemporal Substitution Models 
 Isotemporal substitution models estimated the association with the cardiometabolic 
markers of reallocating daytime activity to or from sleep. The substitution model for each 
cardiometabolic marker included a variable for each daily activity beside sleep duration (SB, 
LIPA, and MVPA), in addition to the 24-hour total wear time variable. Including a total wear 
time variable in the model holds time constant and allows interpretations to be made about the 
cross-sectional associations of cardiometabolic marker levels with reducing the mean time spent 
in one activity by equivalently increasing the mean time spent in another activity. Not including 
the sleep variable in the models allows for interpretation of increasing or decreasing sleep time 
by shifting it from or to another daily activity. Coefficients for each activity were multiplied by 
one standard deviation of the behavior, to model a one standard deviation reallocation of time.  
 Interpretation of the Isotemporal models (and the reallocation of time) requires the 
assumption of a linear relationship among exposure variables and the outcome variables. The 
median average nightly sleep duration time of 8.17 hours was used to stratify the sample as short 
(<8 hours) or long (≥8 hours) sleepers. The isotemporal analyses were stratified across the 
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samples of short (<8 hours) and long (≥8 hours) sleepers to allow for examination of linear 
associations and proper interpretation if sleep duration was increased for short sleepers or 
decreased for long sleepers.  
 Importantly, because these data are cross-sectional, the resulting coefficients cannot be 
interpreted as causal effects, but as estimated effects from the reallocation of 24-hour time. All 
analyses were performed R statistical software version 3.1.1.45 
RESULTS 
 Of the 6489 women in the OPACH sample with accelerometer data, 4580 had valid sleep 
data. One hundred and ninety-two had less than 3 complete days of 24-hour wear, and 1059 did 
not have LSS blood draws, leaving data from 3,329 women available for this analysis. There 
were statistically significant differences in the age and race/ethnicity distributions between the 
current analytic study population and those not included from the OPACH study cohort with at 
least one day of accelerometer data (N=6489). The 3329 women included in the sleep sample 
were slightly older (mean age: 78.9 vs 78.5 years, p<.01), and the included participants had a 
larger proportion of white women (53% vs 45%), and a smaller proportion of African American 
women (30% vs 38%, p<.001) than the original OPACH sample.  
 Socio-demographic and health status characteristics of this analytic sample are presented 
in Table 1.1. Participants had an average age of 78.9 (SD=6.7) years. Over half of the 
participants were white (53.3%) and college educated (78.9%). Only 2.3% of the sample were 
currently smokers and 29.3% were classified as obese. Participants self-reported an average sleep 
disturbance score of 6.3 (SD=4.5) out of 20.  The average nightly accelerometer-measured sleep 
duration for the sample was 490 minutes (SD=72.1) or 8 hours 10 minutes. 
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 Participant characteristics by sleep category are shown in Table 1.1. Women with longer 
sleep durations (<8 hours) were significantly more likely to be older and white. Additionally, the 
longer sleepers were more likely to report higher sleep disturbance scores. Women with shorter 
sleep durations were more likely to be Black or Hispanic and had significantly higher BMIs. 
Distribution of average minutes of time spent in each daily activity by sleep category are 
presented in Table 1.2. On average, long sleepers had more minutes of daily wear time, and sleep 
time, but fewer minutes of MVPA, LIPA, and SB.  
 Results from the single variable sleep regression models are presented in Table 1.3. In 
addition to the model results, estimated mean values for each cardiometabolic marker at 6 hours, 
8 hours, and 10 hours of sleep are presented. Sleep duration was significantly related to insulin 
(p: <0.001), HOMA-IR (p: <0.001), glucose (p: <0.05), total cholesterol (p: <0.05), triglycerides 
(p: <0.001), waist circumference (p: <0.05), and RRS (p: <0.001) in the single variable models. 
The single variable models adjusted for age, race/ethnicity, education, wear time, sleep 
disturbances, self-rated health, smoking status, and comorbid conditions. The quadratic term for 
sleep duration was significant in the CRP (p: <0.05), glucose (p: <0.05), waist circumference(p: 
<0.05), and RRS models (p: <0.001), suggesting the relationship between sleep duration and 
these markers is U-shaped, with higher values for both short and long sleep duration. Results of 
the single variables models for MVPA, LIPA, and SB are presented in Table 1.4. MVPA, LIPA, 
and SB were all significantly related to every cardiometabolic marker after adjusting for age, 
race/ethnicity, education, weartime, sleep disturbances, self-rated health, smoking status, and 
comorbid conditions.  
 The results of the Isotemporal substitution models for short sleepers and long sleepers are 
displayed in Figures 1.2 and 1.3. For the short sleepers, model results estimate the association of 
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reallocating one standard deviation of activity to sleep. For short sleepers, reallocating one SD 
(33 minutes/day) of MVPA to sleep was detrimental across all cardiometabolic markers. 
Reallocating 33 minutes/day of MVPA to sleep was significantly associated with higher values 
of insulin (10%), CRP (4.5%), HOMA-IR(5.5%), glucose (1%), triglycerides (4.6%), waist 
circumference (1%), and RRS (8%). For LIPA, a similar detrimental association was observed in 
some markers when one standard deviation of LIPA (74 minutes/day) was reallocated to sleep. 
Reallocating 74 minutes/day of LIPA to sleep was significantly associated with higher values of 
insulin (9%), CRP (6%), HOMA-IR (4%), and triglycerides (10%). Conversely, reallocating one 
standard deviation of SB (91 minutes/day) to sleep had beneficial associations with some of the 
cardiometabolic markers, including lower values of CRP (9%), waist circumference (1.2%), and 
RRS (2.6%). Very small beneficial associations were observed for insulin, HOMA-IR, and 
glucose when 91 minutes/day was reallocated from SB to sleep. Reallocating one standard 
deviation of LIPA, MVPA, or SB to sleep was detrimentally associated with higher triglyceride 
values.  
 In long sleepers, reallocating time from sleep to MVPA (33 minutes/day) had beneficial 
associations across almost all cardiometabolic markers. Reallocating 33 minutes/day of sleep to 
MVPA was significantly related to lower values for insulin (10.8%), CRP (6.5%) and HOMA-IR 
(5.7%) and RRS (9.5%) and slightly lower levels of glucose (1%), triglycerides (1%), waist 
circumference (1%). Similar results were observed when sleep time was shifted and LIPA was 
increased by one standard deviation (74 minutes), with lower values for insulin (10.3%), CRP 
(15%), HOMA-IR (5.5%), glucose (1%), triglycerides (7%), waist circumference (1.2%), and 
RRS (4.3%). Shifting time from sleep to increase SB time by one standard deviation resulted in 
higher values of CRP (3.3%), triglycerides (1.8%), and waist circumference (1.2%). Very small 
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beneficial associations were observed for insulin (<1%), HOMA-IR (<1%), glucose (<1%), and 
total cholesterol (1%) when one standard deviation of SB (91 minutes) was reallocated from 
sleep to SB. 
 Isotemporal models were repeated after re-categorizing short sleep (<7 hours) and long 
sleep (>9) hours, and although the percent change of associations increased in some markers, the 
direction of associations remained consistent. 
DISCUSSION 
 This is one of the first studies to explore the relationship between objectively measured 
sleep duration and cardiometabolic health in a diverse sample of older women. Our study results 
are consistent with previous single behavior analyses and meta-analyses demonstrating that 
objectively measured sleep duration is significantly related to several markers of cardiometabolic 
health including measures of metabolic function, gluco-regulatory function, and systemic 
inflammation.15,17,46,47 Many studies have focused on the relationship between short sleep and 
glucose metabolism, and the increased risk for diabetes, finding that short sleepers have higher 
glucose levels and increased risk for diabetes.11,48,49 Consistent with this previous research, in our 
analyses, insulin, glucose and HOMA-IR were all significantly related to objective sleep 
duration. Unlike previous results, in our sample the relationship between sleep duration and 
glucose was U-shaped with higher values in both short and long sleepers. Further, in our analysis 
the relationship between sleep and cardiometabolic outcomes appeared to differ across different 
markers, with a linear relationship for some markers and a u-shaped relationship with CRP, 
glucose, waist circumference, and RRS. In our study, the U-shape relationship between sleep 
duration and RRS, suggests that sleep duration, both short and long, is related to higher 10-year 
estimated CVD risk. The individual cardiometabolic marker results, as well as the RRS results, 
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align with previous research suggesting there may be different pathways through which short and 
long sleep duration may be related to increased CVD risk for older women.46 These findings 
contribute to the growing research demonstrating that sleep duration, both short and long, is 
associated with CVD risk.   
 In order to increase or decrease sleep durations to improve cardiometabolic health, time 
would need to be reallocated to or from another behavior in the 24-hour day. While growing 
evidence suggests that sleep duration should be increased in short sleepers or decreased in long 
sleepers, it is not clear what shift in daytime activity would provide benefit. Isotemporal 
modeling techniques allow for the exploration of the associated change in cardiometabolic risk 
of reallocating time spent sleeping when it is shifted to or from LIPA, MVPA, or SB.28,29 Our 
study results support increasing sleep duration in short sleepers and decreasing sleep duration in 
long sleepers, however, these results were dependent on how the 24-hour time was reallocated. 
The results of our isotemporal analysis are consistent with a previous isotemporal modeling 
analysis conducted by Buman et al. that examined cardiometabolic risks associated with 
reallocation of time spent in self-reported sleep, and objectively measured SB and PA among an 
NHANES sample of 2,185 adults (mean age 46.6).29  Consistent with the results of Buman et al, 
our results show that in long sleepers when time was reallocated from sleep to MVPA it was 
associated with favorable values across all of the cardiometabolic makers. In our analysis, a 
similar pattern was observed for reallocating time from sleep to LIPA, a result that was not 
observed in the NHANES sample, and is particularly meaningful in our sample of older women. 
For our sample of older women, achieving shifts to LIPA may be more feasible than shifts to 
MVPA. Further, when time was reallocated from SB to sleep in short sleepers it had beneficial 
associations with several of the cardiometabolic markers, including changes to CRP, waist 
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circumference and RRS. Building upon the results of the NHANES study, our study used an 
objective assessment of sleep duration; measured using accelerometry with an average sleep 
duration calculated from 2-5 nights of sleep and focused on reallocation of time to sleep in short 
sleepers and from sleep in long sleepers. In contrast, the NHANES study assessed sleep duration 
with one item on a questionnaire. Our study results provide support for sleep extension 
interventions in short sleepers, but suggest that how time is reallocated impacts cardiometabolic 
health. These findings have promising value for translation in clinical practice, but require 
testing in randomized controlled trials. In cognitive behavior therapy interventions (CBTI), 
individuals with poor sleep are encouraged to stay out of bed, but keep activity light. Our results 
suggest that interventions targeting sleep extension, and improved sleep should consider 
providing recommendations that are both achievable and provide the most cardiometabolic 
benefits. For short sleepers, replacing SB time in the evening with sleep may be an achievable 
target with cardiometabolic benefits, or for long sleepers reducing SB time in bed and increasing 
LIPA throughout the day may provide benefits. 
 While our study results suggest benefits for increasing or decreasing sleep duration 
overall, results suggest that replacing MVPA or LIPA with sleep in short sleepers and replacing 
sleep duration with SB in longer sleepers are shifts in 24-hour time that are not likely to reduce 
cardiometabolic risk. This finding suggests, that it important to consider the distribution of time 
throughout the 24-hour day, and the impact of interventions on all 24-hour activity when 
designing cardiovascular lifestyle interventions to decrease cardiometabolic risk. When 
developing intervention strategies, it is worthwhile to consider time spent in other activities, 
regardless of the behavioral target of the intervention. For example, our study results suggest that 
in both short and long sleepers, sedentary behavior has a detrimental association with markers of 
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cardiometabolic health and therefore, sleep duration may be an achievable and beneficial 
replacement activity target for interventions targeting SB reduction.  
 When using isotemporal modeling techniques, and when designing behavior change 
interventions, the feasibility of behavior change targets is important. One standard deviation 
change in MVPA, LIPA, and SB is a magnitude of change that may not be realistic for all 
women in the sample. For example, in our analysis, benefits for MVPA were observed with a 33 
minute increase in MVPA, which may not be feasible change for older women when we consider 
the number of older adults meeting PA guidelines. Further a 90 minute increase in sleep duration 
of short sleepers may also not be realistic. Previous sleep extension studies in healthy young 
adults have observed an increase in self-reported sleep duration of approximately 60 minutes.24,50 
The isotemporal modeling approach can show us where a benefit can be expected to occur under 
an ideal shift in time, but the associated magnitude of change is often not realistic. Only 
randomized control intervention trials can inform what change in cardiometabolic markers we 
can truly affect with a change in behavior.  
 A primary strength of our study was the use of accelerometers to measure objectively 24-
hour activity.  The OPACH study employed hip accelerometers, the gold standard for assessment 
of daytime PA; however, wrist placement is considered preferable for assessment of sleep.35,51 
Hip worn accelerometers  provide a more accurate assessment of SB and sleep duration than 
self-reported measures.52–54 Additionally, we employed thoughtful data processing steps to 
ensure the accuracy of our behavior classification. The in-bed sleep period was defined using 
participant sleep logs and visual coding, to ensure further the accuracy of the in-bed period. 
Older women have lower levels of activity throughout the day, which may lead algorithms to 
misclassify SB as sleep. The visual inspection of in-bed time not only provided more accurate 
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estimates of sleep duration, but also more accurate estimates of SB, by capturing in-bed 
sedentary time. In-bed sedentary time is often omitted when SB data processing protocols 
remove in-bed time from their analyses. Distinguishing between sleep and in-bed sedentary time 
is important as lying in bed in bed awake does not have the same benefits as sleeping.  
 Our study population includes only post-menopausal older women from the unique WHI 
sample, and therefore may not be generalizable to men or other age groups. However, the study 
population included larger numbers of older African American and Hispanic women than 
previous studies that have assessed the relationship between sleep duration and cardiometabolic 
health. Further, this study is cross-sectional, limiting our ability to make causal inferences about 
the reallocation of time spent in one behavior to another. Our study findings do not represent 
actual activity replacement, but the estimated results of modeling shifts in population-level data. 
Lastly, our study would have benefited from objective measurement of postural change to 
estimate SB and the time that older woman spend in bed not sleeping.  
 Cardiovascular interventions for older women should continue to target increasing LIPA 
and MVPA and reducing SB, but also consider sleep duration as a lifestyle risk factor worth 
targeting for cardiometabolic risk reduction. Designing sleep duration interventions or including 
sleep behavioral targets in existing lifestyle interventions, may provide a feasible target for older 
women who are short or long sleepers. Future research should explore the interrelationships of 
activity throughout the 24-hour day, including using a compositional approach to statistical 
analyses. Moreover, future cardiovascular lifestyle interventions should examine further the 
possibility of multiple behavior targets, including more specific activity replacement targets, and 
tailoring intervention targets for feasibility.    
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Figure 1.1: OPACH study participant flow diagram 
  
Excluded (n=1943)
• No wear at night (n= 1453)
• No sleep log (n=438)
• No GT3x file (n=18)
OPACH Participants with 
Accelerometer Data 
n=6489
Excluded from analysis  (n=1211)
• No LLS biomarker data (n=1059)
• <3 24-hour days of wear (n=192)
OPACH
Consenting Sample
n=7048
OPACH Sleep Sample
n= 4580
OPACH 24-Hour 
Analysis Sample
N=3329Figure 1. OPACH Study 
Participant Flow Diagram
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Table 1.1: Participant characteristics for the OPACH cohort by sleep duration categories  
 
Full Sample 
N=3329 
 
Short Sleepers 
<8 hours 
n=1486 
Long Sleepers 
≥8 hours 
n=1843 
P-
value 
     
 
Mean ± SD 
N (%) 
Mean ± SD 
N (%) 
Mean ± SD 
N (%) 
 
Age, years 78.9 ± 6.7 78.0 ± 6.6 79.7 ± 6.7 <.001 
  63-69 330 (9.9) 179 (12.0) 151 (8.2) <.001 
  70-79 1275 (38.3) 623 (42.0) 652 (35.4)  
  80-89 1576 (47.3) 635 (42.7) 941(51.1)  
  ≥90 148 (4.4) 49 (3.3) 99 (5.4)  
Race-ethnicity    <.001 
  White 1782 (53.5) 734 (49.4) 1048 (56.9)  
  Black 991 (29.8) 482 (32.4) 509 (27.6)  
  Hispanic 556 (16.7) 270 (18.2) 286 (15.5)  
Education    0.71 
  High school or less 686 (20.6) 310 (20.9) 376 (20.5)  
  Some college 1285 (38.6) 563 (38.0) 722 (39.4)  
  College graduate 1340 (40.3) 607 (41.0) 733 (40.0)  
Current smoker 78 (2.3) 43 (2.9) 35 (1.9) 0.08 
Sleep Disturbance Score 6.3 ± 4.5 6.0 ± 4.4 6.5 ± 4.5 <0.01 
BMI, kg/m2 27.8 ± 5.7 28.2 ± 5.8 27.6 ± 5.5 <0.01 
  ≥30 (obese) 976 (29.3) 460 (31.2) 516 (28.2) 0.12 
Comorbidity Index 
≥2 comorbidities 
518 (15.6) 202 (13.6) 316 (17.1) <.01 
Self-report Health  
At least good 
 
2792 (83.9) 
 
1277 (92.9) 
 
1515 (89.0) 
 
<.001 
BMI, body mass index 
Note: Numbers do not sum to total due to missing data 
Table 1.2: Summary of 24-hour time spent in each daily activity by sleep category 
 Short sleepers (<8 hours) Long sleepers (≥8 hours) 
 Mean (SD) Mean (SD) 
Wear time (mins/day) 1370.32 (44.2) 1388.35 (43.1) 
MVPA (mins/day) 55.69 (37.2) 44.15 (31.2) 
LIPA (mins/day) 298.76 (77.2) 257.85 (71.1) 
SB (mins/day) 593.66 (93.9) 541.91 (84.6) 
Sleep (mins/day) 428.32 (42.4) 539.74 (50.2) 
   
MVPA: moderate to vigorous physical activity 
LIPA: light physical activity 
SB: sedentary behavior 
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Table 1.3: Single variable models1 for sleep duration and estimated cardiometabolic markers 
1 Models adjusted for weartime, age, race/ethnicity, education, sleep disturbances, self-rated health, smoking status, and comorbid 
conditions 
2 Reynolds Risk Model did not include age in adjustments – age is included in Reynolds Risk Score calculation 
++Beta coefficients are log transformed and reflect associations for 10 mins of sleep duration 
 
 
 
 
 
 6 
hours 
8 
hours 
10 
hours 
 
B++ SE p value 
Insulin (mmol/L)        
 59.39 63.22 70.88 Linear term 0.952 0.021 <0.001 
    Quadratic term  -- -- -- 
C-Reactive Protein (mg/L)        
 1.77 1.78 2.04 Linear term -3.903 0.242 0.11 
    Quadratic term  0.005 <0.001 0.05 
HOMA-IR        
 1.41 1.48 1.57 Linear term 0.447 0.010 <0.001 
    Quadratic term  -- -- -- 
Glucose (mg/dL)        
 98.28 97.23 100.11 Linear term -1.226 0.063 <0.05 
    Quadratic term  0.001 <0.001 <0.05 
HDL cholesterol (mmol/L)        
 61.20 60.88 60.57 Linear term - 
0.026 
0.004 0.53 
    Quadratic term  -- -- -- 
Total cholesterol (mmol/L)        
 194.01 197.13 200.26 Linear term 0.257 0.011 <0.05 
    Quadratic term  -- -- -- 
Triglycerides (mg/dL)        
 89.79 96.60 103.95 Linear term 0.006 0.012 <0.001  
    Quadratic term  -- -- -- 
Systolic Blood Pressure        
 125.17 125.38 125.58 Linear term 0.017 0.004 0.67 
    Quadratic term  -- -- -- 
Waist Circumference (cm)        
 90.20 88.91 89.34 Linear term -0.608 0.031 <0.05  
    Quadratic term  0.001 <0.001 0.05 
BMI (kg/m2)        
 27.9 27.78 27.65 Linear term -0.011 0.001 0.46 
    Quadratic term  -- -- -- 
Reynolds Risk Score (%)2        
 12.02 11.68 14.69 Linear term -1.011 0.024 <0.001  
    Quadratic term  0.001 <0.001 <0.001  
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Table 1.4: Single variable models1 for MVPA, LIPA, and SB and cardiometabolic markers 
  B++ SE p value 
Insulin (mmol/L)     
 MVPA -4.239 0.044 <0.001 
 LIPA -1.855 0.019 <0.001  
 SB 1.061 0.015 <0.001  
C-Reactive Protein (mg/L)     
 MVPA -4.080 0.061 <0.001 
 LIPA -2.496 0.027 <0.001 
 SB 1.611 0.021 <0.001  
HOMA-IR     
 MVPA -2.185 0.022 <0.001  
 LIPA -0.907 0.010 <0.001  
 SB 0.544 0.008 <0.001  
Glucose (mg/dL)     
 MVPA -0.985 0.016 <0.001 
 LIPA -0.274 0.007 <0.001  
 SB 0.217 0.006 <0.001  
HDL cholesterol (mmol/L)     
 MVPA 0.777 0.009 <0.001  
 LIPA 0.408 0.004 <0.001  
 SB -0.328 0.003 <0.001  
Total cholesterol (mmol/L)     
 MVPA 1.317 0.023 <0.001  
 LIPA  0.210 0.010 <0.05  
 SB -0.444 0.008 <0.001 
Triglycerides (mg/dL)    <0.001 
 MVPA -1.835 0.026 <0.001 
 LIPA  -1.287 0.011 <0.001 
 SB 0.671 0.009 <0.001 
Systolic Blood Pressure     
 MVPA -0.276 0.008 0.001 
 LIPA -0.155 0.004 <0.001 
 SB 0.121 0.003 <0.001 
Waist Circumference (cm)     
 MVPA -1.155 0.008 <0.001 
 LIPA -0.556 0.003 <0.001 
 SB 0.480 0.003 <0.001 
BMI (kg/m2)     
 MVPA -0.382 0.003 <0.001 
 LIPA -0.222 0.001 <0.001 
 SB 0.183 0.001 <0.001 
Reynolds Risk Score (%)2     
 MVPA -0.838 0.006 <0.001 
 LIPA -0.300 0.003 <0.001 
 SB 0.216 0.002 <0.001 
1 Models adjusted for weartime, age, race/ethnicity, education, sleep disturbances, self-rated health, smoking 
status, and comorbid conditions 
2 Reynolds Risk Model did not include age in adjustments – age is included in Reynolds Risk Score calculation 
++Beta coefficients reflect associations for 10 mins of activity 
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CHAPTER 2 
Association between Accelerometer-Measured Sleep Duration and Clinical Cardiovascular 
Risk Factor Scores in Older Women 
ABSTRACT 
 Background: Emerging evidence suggests that sleep duration, both short and long, is a 
potential modifiable lifestyle factor associated with cardiovascular disease (CVD). However, 
research on sleep duration and CVD risk is limited by use of self-report sleep measures, 
homogeneous populations, and studies on individual CVD risk factors. As women age their risk 
of CVD increases, as does their risk for sleep disturbances. Based on this framework, we sought 
to test the hypothesis that accelerometer-measured sleep duration would be related to estimated 
CVD risk among a diverse group of aging women.  
 Methods: Cross-sectional data were analyzed in 3369 racial/ethnically diverse older 
women (mean age 78.9 years; 53.3% white, 29.9% black, 16.8% Hispanic), from the Objective 
Physical Activity and Cardiovascular Health Study, an ancillary study to the Women’s Health 
Initiative. Women wore ActiGraph GT3X+ accelerometers on the hip for 24 hours per day and 
completed a daily sleep log over a 7-day period. A composite of 10-year estimated CVD risk, the 
Reynolds Risk Score (RRS), was computed using age, systolic blood pressure, high-sensitivity 
C-reactive protein (CRP), total and HDL cholesterol, diabetes mellitus status, smoking status, 
and family history of premature myocardial infarction. Average nightly sleep duration was 
derived from accelerometer data. A series of progressively adjusted linear regression models 
investigated the strength of the association between sleep duration and RRS.  
 Results: Results suggested a U-shaped relationship between sleep duration and RRS, 
such that both short and long sleep are associated with higher RRS. The association remained 
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significant after adjustments for race/ethnicity, education, lifestyle factors, BMI, self-reported 
sleep disturbances, sleep medications, and comorbidities.  
 Conclusions: In older women, actigraphy-ascertained sleep duration was associated with 
10-year estimated CVD risk. Both short and long sleep were related to higher RRS in 
multivariable adjusted analyses. This study, based on accelerometer-measured rather than self-
reported sleep, supports sleep duration as a modifiable risk factor for CVD in older women. 
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INTRODUCTION 
 Cardiovascular disease (CVD) poses a serious risk to the growing aging population of 
women in the United States.1 According to the American Heart Association, more than one in 
three US women currently has some form of CVD.2 Women over the age of 80 years have a 
higher incidence of CVD events than their male counterparts.2 The American Heart Association 
estimates that approximately 90% of women in the United States are currently living with one or 
more risk factors for developing CVD.2 There are a number of modifiable risk factors for CVD 
including obesity, physical inactivity, elevated total cholesterol, reduced HDL cholesterol, 
diabetes, smoking, hypertension, and systemic inflammation as measured by elevated high-
sensitivity C-reactive protein (CRP).3 Cardiovascular prevention strategies for women focus on 
the promotion of daily physical activity and a well-balanced diet.2 The continuing high burden of 
clinical CVD and its risk factors among women suggest that enhancing current prevention 
strategies could be warranted to achieve better control of CVD at the population level.  
 Emerging evidence suggests that sleep duration, both short (<7 hours) and long (>9 
hours), is a potential lifestyle risk factor for CVD.4 A number of cross-sectional and prospective 
observational studies demonstrate that self-reported short sleep (<7 hours) is a predictor of 
incident cardiometabolic conditions such as type 2 diabetes, hypertension, and obesity.5–10 A 
meta-analysis of prospective studies examining the relationship between self-reported sleep 
duration and coronary heart disease (CHD), found that among a total sample of 249,324 adults, 
short sleepers (those sleeping less than 7 hours) had an approximate 50% increase in risk of 
developing or dying from CHD when compared with normal sleepers (those sleeping 7-8 
hours).11 Additionally, those who reported long sleep durations (more than 8 hours) experienced 
a 38% increased risk of CHD when compared to normal sleepers.11 
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 Previous evidence of the relationship between sleep duration and CVD risk is not without 
limitations. The majority of published studies have relied on self-reported sleep duration from 1 
or 2 survey items, and have focused on study samples primarily consisting of middle-aged non-
Hispanic white adults.12 While CVD incidence is higher in older women, and African American 
and Non-white Hispanic populations2, most published studies on sleep and CVD risk have not 
adequately included women with broad representation from these age and race-ethnic groups.4,13 
Additionally, evidence has demonstrated that sleep duration and quality differs across age groups 
and racial/ethnic groups.14,15 According to the American Heart Association Scientific Statement 
on the relationship between sleep duration and CVD, inclusion of these understudied 
populations, including aging women and African American and Non-white Hispanic women, and 
the objective assessment of sleep, should be high priorities for future research.4 Further, previous 
studies have primarily examined the relationship between sleep duration and individual CVD 
risk factors such as systolic blood pressure and BMI, with reviews and meta-analyses compiling 
data to draw conclusions about overall cardiometabolic risk.11–13,16 While examining CVD risk 
factors individually may explain the relationship between sleep and cardiometabolic health at a 
given point in time, they may not explain the relationship between sleep and risk of future CVD. 
Further, in the clinical setting, composite risk factor scores are the conventional first-line 
approach to predict an individual’s future CVD risk and to help decide need for further testing 
(e.g. stress testing, coronary calcium measurements) and initiation of therapeutic intervention.17  
 The objective of this paper is to examine the relationship between accelerometer-
measured sleep duration and estimated CVD risk (using the Reynolds Risk Score) in a large 
racially/ethnically diverse cohort of older women. The Reynolds Risk Score (RRS) is used 
clinically to predict 10-year risk of CVD.18 This analysis will test the hypothesis that 
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accelerometer-measured sleep duration is related to CVD risk among a diverse group of aging 
women. Results from this analysis could inform the potential utility of including sleep duration 
in clinical guidelines on CVD prevention.  
METHODS 
Study Sample 
 Women in the study were enrolled for participation in the Objective Physical Activity 
and Cardiovascular Health (OPACH) study, an ancillary study to the Women’s Health Initiative 
(WHI). From 1993 to 1998, postmenopausal women between the ages of 50 to 79 years were 
enrolled in the WHI Clinical Trials or the Observational Study from 40 clinical sites throughout 
the US. Participants in the WHI studies continue to be followed annually for disease events, 
changes in health status, and death. To be eligible and enrolled in Extension Studies women were 
required to be alive, willing to be contacted, and willing to provide additional informed consent. 
The OPACH study aimed to examine prospectively the relationship between accelerometer-
measured physical activity and incidence of CVD in older women. Information on the OPACH 
study objectives, recruitment, and methodology have been previously published.19 Between 
2012-2013, women participating in the WHI Long Life Study (LLS) completed in home health 
assessments to assess factors associated with healthy aging and cardiovascular health. In home 
data collection included fasting blood draws, personal health and lifestyle questionnaires, 
anthropometric measurements, and blood pressure and pulse assessments. A subset of LLS 
participants (N=7048) agreed to participate in the OPACH study, received GT3x accelerometer 
devices, and were asked to wear them on their waist for 24 hours per day over a 7-day period.  
Additionally, participants were asked to complete sleep logs and report their in-bed time and out-
of-bed time for the 7-day accelerometer wear period. Of the 7048 consented participants, 6,489 
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women returned their devices and provided at least one day of valid accelerometer data (≥10 
hours/day wear time); 4,580 of these women had valid night wear and completed sleep logs. Of 
these, 3,369 met eligibility criteria for inclusion in this analysis, including completion of at least 
3 nights of valid accelerometer data, a completed sleep log that overlapped with accelerometer 
nights, and information on fasting blood lipids (Figure 2.1). In consideration of night to night 
sleep variation, previous sleep studies have demonstrated that one night of accelerometer wear is 
not sufficient to assess regular sleep habits.20 Additionally, previous cohort studies examining 
cardiovascular health have defined valid wear as three nights.21  
Accelerometer-Measured Sleep Duration 
 Sleep duration was assessed with the hip-worn triaxial accelerometer (Actigraph GT3X+; 
Pensacola, FL). Participants were asked to wear the accelerometer device secured to their hip 
with a belt, 24 hours a day for 7 consecutive days, except for time spent bathing or swimming. 
Data were recorded in 1-second epochs collected at a frequency of 30 Hertz. In addition, 
participants were asked to complete a daily sleep log recording time in bed and time out of bed. 
Although wrist-worn accelerometer devices are more standard for sleep assessment, hip-worn 
accelerometers are the norm for physical activity studies like OPACH.22,23 Outside of the lab 
setting, the use of hip accelerometers to assess sleep duration has been shown to be valid for 
assessment of total sleep duration against the gold standard polysomnography.23,24 
Accelerometer estimated sleep duration is considered more accurate than self-reported sleep 
duration or sleep logs alone,25 especially in older adult populations where cognitive issues may 
be present.26   
 After the device was returned, raw data were processed using ActiLife version 6.11 
software. Raw data were condensed to 60 second AGD files with the low frequency extension 
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filter. AGD files were scored for sleep variables using a standard protocol. A trained member of 
the research team identified the primary sleep window using the participant sleep logs and visual 
review of the data for each night the participant wore the device. This procedure draws from a 
protocol shown previously to have high interrater reliability.27 The validated Cole-Kripke 
algorithm28 classified the sleep interval on a minute by minute basis as sleep or wake and 
estimates of nightly sleep duration were derived as the total amount of time classified as sleep 
(minutes/night) during the primary sleep period. Mean sleep duration was calculated across the 
available days of scored sleep (ranging from 3-7) to create an average nightly sleep duration 
variable. Previous studies have examined short sleep duration as <6 or <7 hours of sleep/night 
and long sleep duration as >9 or >10 hours of sleep/night, due to self-reported assessment 
response categories. Because a clear and well-established definition of short or long sleep 
duration currently does not exist, we conducted our analysis retaining sleep duration as a 
continuous variable.  
10 Year Estimated CVD Risk: Reynolds Risk Score 
 The Reynolds Risk Score (RRS) for 10-year predicted CVD risk was calculated as a 
composite variable which has demonstrated accuracy in the prediction of future CVD occurrence 
in women, as described elsewhere.18 RRS is calculated using age, systolic blood pressure (SBP), 
CRP, total and HDL cholesterol, diabetes mellitus status, smoking status, and family history of 
premature myocardial infarction. In a previous study conducted in the WHI cohort the RRS 
demonstrated good validity in the prediction of actual CVD events, and performed better in the 
validation cohort of older woman than the Framingham ATP-III Score.29 Hemoglobin A1c was 
not assessed in the OPACH study; therefore, this variable was not included in the RRS 
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calculation (for those who report a history of diabetes diagnosis as specified in the RRS scoring 
protocol). 
 At the LLS home visit, blood samples were obtained. Participants were instructed to fast 
for 12 hours prior to the blood draw. Samples were centrifuged within 2 hours of blood draw, 
and shipped overnight priority mail to the Fred Hutchinson Cancer Research Center Specimen 
Processing Laboratory (Seattle, Washington). An aliquot for each participant was sent from the 
WHI Biorepository to the University of Minnesota Fairview ARDL Laboratory for CVD 
biomarker testing. The biomarkers required in the RRS were obtained from these test results. 
Resting blood pressure (BP) was measured after a 5-minute rest period using an aneroid 
sphygmomanometer and cuff size based on measured arm circumference. The average of two BP 
readings was recorded. Diabetes mellitus status, smoking status, and family history of premature 
myocardial infarction were assessed using the LLS questionnaire.  
Covariates 
 LLS and WHI questionnaires ascertained demographic information, education, alcohol 
intake, smoking, self-reported physical functioning, self-rated heath, self-reported sleep 
disturbances, sleep medication use, and history of chronic conditions.  
 Education was categorized into 3 levels: high school or less, some college, college 
graduate or more. Alcohol intake was measured with 1-item assessing the frequency of 
consuming gram standardized alcoholic drinks the past three months. Response options ranged 
on a 5-point scale from “never” to “everyday”. Physical functioning was assessed with the 
RAND 36-item health survey.30 A score was calculated ranging from 0-100, with higher values 
signifying better physical functioning. Self-rated health was assessed with 1-item from the WHI 
lifestyle questionnaire asking participants “In general would you say your health is…”. Response 
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options ranged on a 5-point scale from “excellent” to “poor”. Depression was assessed with the 
WHI Depression Scale,31 a short form adaptation of the CES-D scale. Scale scores ranged from 
0-1 with higher values indicating a higher presence of depressive symptoms. Sleep disturbances 
were assessed with the WHI Insomnia Rating Scale (WHIIRS).32 A scale score is calculated 
from the five item scores (0-4) to create a global sleep disturbance score ranging from 0-20. A 
higher WHIIRS score is reflective of greater presence of sleep disturbances and has been shown 
to be predictive of CVD.33 The use of sleep medications was assessed with 1-item assessing in 
the last 4 months, how many times per week a participant used sleep medications. Response 
options ranged from “None in the past 4 weeks” to “5 or more times per week”. A comorbidity 
index variable was created using the self-report of existing chronic conditions collected in the 
baseline survey. The index included self-report of history of chronic obstructive pulmonary 
disease (COPD), history of osteoarthritis, history of cerebrovascular disease, history of cancer, 
history of cognitive impairment, and history of hip fractures. The number of conditions was 
summed to create a comorbidity index score (0-6).  
 Height (cm) and weight (kg) were measured using a portable scale and stadiometer. 
Participants Body Mass Index (BMI; kg/m2) was calculated with the height and weight obtained 
at the LLS study visit. Total daily physical activity (minutes/day) were measured using the GT3x 
accelerometer.  
Statistical Analysis 
 Descriptive analyses tested for differences in demographic, medical and behavioral 
factors in the sample across four categories of sleep duration using One-Way ANOVAs for 
continuous variables and Chi-square tests for proportions. 
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 Progressively adjusted linear regression models and marginal means plots were used to 
evaluate the relationship between average nightly sleep duration and RRS. The first model was 
minimally adjusted for race/ethnicity and education. Because age is included as a component of 
the RRS, it was not adjusted for in the regression models. The second series of adjustments 
included alcohol intake, total minutes of physical activity, sleep disturbance score, and sleep 
medications. Further adjusted models included BMI, physical functioning, comorbidity index 
score, depression, and self-rated health, all of which could potentially mediate an association 
between sleep duration and estimated CVD risk. 
 The literature suggests both short and long sleep durations are related to increased risk for 
CVD. Therefore, we tested if the relationship between sleep and RRS was non-linear by 
including a quadratic term for sleep duration in this series of models.  
 All analyses were performed using R statistical software version 3.1.1.34 
RESULTS 
 In this cross-sectional analysis, we excluded the participants who had fewer than 3 nights 
of accelerometry data (n=152) or were missing biomarker data (n=1059), resulting in a final 
analytic sample of 3,369 women. There were statistically significant differences in the age and in 
the proportion of the race/ethnicity groups between the subsample of women with 3 valid nights 
of accelerometer than women in the entire OPACH study who returned at least one day of 
accelerometer data (N=6489); however, there were no significant differences based on hours of 
self-reported sleep duration. The 3369 women included in the sleep sample were slightly older 
(mean age: 78.9 vs 78.5 years, p<.01), and the sample had a larger proportion of white women 
(53% vs 45%), and a smaller proportion of African American women (30% vs 38%, p<.001) 
than the original OPACH sample.  
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 The analytic sample had an average nightly sleep duration of 8.16 hours (SD: 71.4). 
There were 517 (15.3%) women who had an accelerometer-measured sleep duration of less than 
7 hours, 975 (29.0%) between 7 and 8 hours, 1149 (34.1%) between 8 and 9 hours, and 728 
(21.6%) greater than 9 hours. Characteristics of the study sample are presented for descriptive 
purposes according to sleep duration quartiles in Table 2.1.  
 The average age of women in the sample was 78.9 years (SD:6.7), and 53.3% of women 
were white, 29.9% black, and 16.8% Hispanic. Over 80% of participants had at least some 
college level education. Over 60% of the sample reported drinking some alcohol and only 2.3% 
were currently smokers.  The average sleep disturbance score of the sample was 6.3 out of 20 
(SD: 4.5). Over 18% of the sample reported presence of 2 or more comorbidities, but 83.9% 
reported at least good general health. The mean BMI among all women was 27.9 kg/m2, with 
almost 1/3 of women in the sample categorized as obese (BMI >30 kg/m2), and 19.4% of the 
sample had a history of diagnosed or treated diabetes mellitus.   
Women who slept less than 7 hours were, on average, significantly younger and more 
likely to be African American or Hispanic as compared to women with longer sleep durations. 
Education level did not differ across the sleep categories. The short sleepers (<7 hours) were less 
likely to be regular drinkers, had a lower sleep disturbance score, and higher levels of daily 
physical activity than women in the other sleep categories. Short sleepers were also more likely 
to be current smokers and have a diabetes diagnosis compared to non-short sleepers.  
 Women in the 7-8 hour and 8-9 hour categories were more likely to be white women than 
African American or Hispanic. Drinking more than 5 alcoholic drinks per week was more 
commonly reported by women who slept in the 7-8 and 8-9 hour categories than in the other two 
categories.  
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 Sleep disturbance scores, reported sleep medication use, depression, and the proportion of 
the sample with more than 2 comorbidities was highest in the >9 hours of sleep category. 
Additionally, physical functioning scores, total daily physical activity, and the proportion of the 
sample reporting good to excellent self-rated health were lowest among women in the >9 hours 
of sleep category.  
 Differences in the individual components of the Reynolds risk Score were examined 
across sleep duration categories and no significant differences were observed in the individual 
risk factors between categories, except for smoking status, which was higher among short 
sleepers. Of note, women in both the <7 hours of sleep category and the >9 hours of sleep 
category had a higher prevalence of diabetes than women in the 7-8 and 8-9 hours of sleep 
categories.  
 After adjustment for race/ethnicity and education, both sleep duration and the quadratic 
sleep duration term were significantly related to RRS (Figure 2.2; sleep duration: B: -0.11 
p<0.001, sleep duration2 B: <0.00 p<0.001).  Figure 2.2 displays this minimally adjusted 
relationship between accelerometer-measured sleep duration and RRS. The relationship appears 
to be U-shaped, with both short (<400 minutes/night; <6.5 hours/night) and long (>500 
minutes/night; >8 hours/night) sleep associated with higher RRS as compared to the middle of 
the sleep duration distribution. In the series of progressively adjusted models the quadratic sleep 
duration term was significantly associated with RRS after adjustments for lifestyle factors 
including alcohol intake, physical activity, sleep disturbances, and sleep medications (Figure 2.3; 
sleep duration2 B: <0.00 p<0.001). Results were similar after further adjustment for BMI, 
physical functioning, comorbidity index score, depression, and self-rated health. In this final 
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model sleep duration remained significantly related to RRS after adjustment (Figure 2.4; sleep 
duration2 B: <0.00 p<0.01).  
 The series of progressively adjusted models are illustrated in Figures 2.2-2.4 to show the 
u-shaped relationship between sleep duration and estimated 10-year CVD risk. While the 
coefficients for the quadratic sleep duration variables in the series of progressive adjustments do 
not reflect attenuation, the plots show the shape of the curve changing after adjustment. Despite 
the change in the shape of the plots, the relationship between sleep duration and RRS remains 
significant, with both short and long sleep associated with higher RRS. Table 2.2 provides the 
estimated RRS from the series of models for each hour per night of sleep. The table provides a 
quantification of what is shown in the figures, with both short, and long sleep durations related to 
higher RRS. The relationship between long sleep duration (>10 hours) and RRS is very clearly 
attenuated after the progressive adjustment. Further, the relationship between shorter sleep 
duration (<6 hours) and RRS appears to become stronger after the series of adjustments. 
 Although age is a risk factor for CVD and is related to sleep, our main analysis does not 
adjust for age, as it is a component of the RRS. Adjustment for a variable that is included in the 
composite RRS could lead to over adjustment of the models.  We did, however, complete a 
sensitivity analysis to further explored if the relationship between RRS and sleep was consistent 
in older and younger women by stratifying our final model by age. The relationship between 
sleep duration and RRS was not significant in younger women (<80 years; sleep duration: B: -
0.025 p=0.25, sleep duration2 B: <0.00 p=0.29), but remained significant in older women (>80 
years; sleep duration: B: -0.083 p<0.05, sleep duration2 B: <0.00 p<0.05).  
 
 
 68 
DISCUSSION 
 This cross-sectional study of older women is one of the largest studies published to 
provide additional evidence that sleep duration, measured with accelerometry, is associated with 
a measure of CVD risk in women. We observed significant associations of sleep duration with 
10-year estimated CVD risk, measured by the composite Reynolds Risk Score, which persisted 
after progressively adjusting for demographics, known lifestyle CVD risk factors, and other 
possible confounders including sleep medication use. The nature of the relationship between 
sleep duration and CVD risk remains a topic of investigation and our study suggest that sleep 
duration is non-linearly related with estimated CVD risk among older women in the community. 
Both shorter- and longer sleep duration was associated with higher 10-year CVD risks estimated 
by the RRS. Prospective studies that relate objectively measured sleep duration with the 
incidence of CVD events are need to clarify the cross-sectional findings of the present study. 
 Our analysis builds upon previous evidence demonstrating a relationship between sleep 
duration and CVD risk. The Sleep Heart Health Study, a community-based sample of 5910 adult 
men and women over the age of 40 years, assessed sleep duration with a one item self-report. 
The relative odds of hypertension were 60% (OR 1.60, 95% CI, 1.35-2.04) and 30% (Or 1.30, 
95% CI, 1.04-1.62) higher in participants sleeping fewer than 6 hours and more than 9 hours per 
night, respectively, when compared with those sleeping 7 to 8 hours per night.35 Consistent with 
our results, the Sleep Heart Health Study reported a u-shaped relationship between sleep duration 
and risk of hypertension. The Wisconsin Sleep Cohort Study included 1,024 men and women, 
mean age of 52.7, whose sleep was evaluated using overnight polysomnography. A U-shaped 
association between sleep duration and obesity was observed, with individuals who sleep less 
than and  more than 7.5 hours per night having increased likelihood of obesity.36 In the Chicago 
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Area Sleep Study on 650 adult men and women, ages 35-64, there was no relationship found 
between sleep duration measured by actigraphy and cardiometabolic markers including 
hypertension, diabetes, or obesity.37 The authors attributed the absence of findings to the longer 
average sleep duration and an unusual lack of short sleepers in their sample. These results may 
also be due to the small study sample. We had a larger sample with a greater proportion of both 
short and long sleepers, which may explain the significant findings of both the linear and 
quadratic term in our study results. Additionally, we did not focus on assessing a relationship 
between sleep duration and a single CVD risk factor such as obesity or hypertension, but rather a 
composite clinical risk factor score, RRS, which takes into account both the number and relative 
contribution of the individual risk factors in estimating the 10-year risk of a cardiovascular event. 
In our sample, many of the individual risk factors for CVD, including systolic blood pressure and 
BMI did not differ significantly across sleep duration quartiles. These results suggest that 
assessing the relationship between sleep duration and individual CVD risk factors may not 
sufficiently reflect the increased risk for future CVD events associated with short or long sleep 
duration.  
 The average age of women in the OPACH sleep sample was almost 79 years, making this 
one of the oldest cohorts in which the relationship between accelerometer- measured sleep 
duration and CVD has been examined. In a previous WHI study among 86,329 older women, 
ages 50-79 (84% white), the relationship between sleep duration measured by one-item self-
report and incident CHD and CVD was examined.33 In models adjusted for age and race, short 
(<5 hours) and long (>10 hours) sleep duration was associated with a significantly higher risk of 
CHD (25% and 43%) and CVD (19% and 37%), however results did not remain significant after 
further adjustment.33 Our results are similar to the results of the minimally adjusted models, with 
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an increase in estimated risk observed in both short and long sleepers. Though the sample of this 
previous WHI study is similar, our study sample is older (mean age of 78.9 years) and 
substantially more diverse (only 53.5% white). The oldest women (>80 years) comprised most of 
the long sleep quartile (>9 hours). Older age may be an additional risk factor for long sleep that 
has not been sufficiently examined.38 Further, the results of our sensitivity analysis demonstrate 
that the relationship between sleep duration and RRS does differ between younger and older 
women in our cohort. Thus, it appears that sleep might influence CVD risk factors and their 
integrated effect on predicted risk of a future CVD event differently in older compared with 
younger women. Additional research is needed to better understand how sleep and age interrelate 
with propensity for cardiovascular disease. 
 While the existing literature on the detrimental effects of long sleep are mixed, studies 
have shown that long sleep durations are associated with increased risk of chronic conditions and 
increased risk of mortality.39–42 We add to this literature, demonstrating that accelerometer-
measured long sleep duration is related to increased 10-year estimated CVD risk. While we 
controlled for comorbidities, self-reported sleep disturbances, depression, and other possible 
confounders that may partially explain this relationship, with cross-sectional data we are not able 
to examine the potential pathways through which sleep duration is linked to estimated CVD risk. 
Studies suggest there are several biological pathways through which short sleep is related to 
cardiometabolic health, including: alterations in glucose metabolism,43 insulin resistance,44 
appetite regulation,4 and inflammation.45 The mechanisms between long sleep duration and 
cardiometabolic health are not as clear, however after controlling for possible confounders (e.g. 
physical activity, depression, sleep medications) studies have shown that long sleep durations are 
also related to markers of gluco-regulatory function and systemic inflammation.46,47 Similar to 
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previous studies, we tried to adequately control for factors related to health and sleep duration, 
including depression, socio-economic status, physical functioning, physical activity, and sleep 
medications. After these adjustments the relationship between short and long sleep duration and 
estimated CVD risk remained significant.    
 The primary strength of our study was the use of actigraphy to measure sleep duration, a 
more accurate assessment of sleep duration than a self-reported measure. Previous cohort studies 
have relied upon 1- or 2-item self-reported measures of sleep duration to examine how sleep 
duration may be related to CVD risk. Validity studies have shown that individuals are likely to 
report sleep times that align with what is perceived as acceptable and often are over-reporting 
their sleep time.48,49 While evidence suggests the prevalence of self-reported poor sleep and short 
sleep varies across racial/ethnic groups,50 less is known about how reporting bias may vary 
across these groups. Our study employed hip accelerometers, which are less commonly used for 
sleep assessment, but have been validated for total sleep duration.51,52 Additionally, we employed 
additional data processing and quality control steps to ensure the accuracy of the data. The in-bed 
sleep period was defined using participant sleep logs and visual coding protocol by a team of 
trained coders, to ensure further the accuracy of the in-bed and out-of-bed participant reports. 
This method is used in place of an automated in-bed algorithm, which was not developed for hip 
accelerometers or for use in older adult samples. Older women have lower levels of activity 
throughout the day and especially at night, which may lead an algorithm to misclassifying hours 
or sedentary behavior as sleep time. In addition, our participant sample was purposefully 
recruited to have larger numbers of racial-ethnic minorities including African Americans and 
Hispanics who tend to report, on average, shorter sleep durations15 and have higher prevalence of 
CVD risk factors.53 Prior studies that included objective assessment of sleep duration typically 
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only have compared two racial-ethnic  groups (e.g., non-Hispanic whites vs. African Americans), 
and not large proportions of women from racial-ethnic groups with wide age ranges.35,54  
 This study has some limitations. As is common with sleep studies, the amount of sleep 
that leads to the best health outcomes can vary by individual. These study results and conclusions 
drawn regarding sleep duration and CVD risk reflect the risk associated with average sleep 
durations across a large sample of women. Additionally, our study sample includes only post-
menopausal older women, and therefore is not generalizable to the population as a whole. 
Further, our exposure variable, sleep duration, was only assessed at one time point, and therefore 
the influence that changes in sleep duration over time have on the relationship between sleep 
duration and CVD risk cannot be evaluated in this study. The relationship between 
accelerometer-measured sleep duration and CVD risk was not the primary aim of the OPACH 
study and therefore there was not implementation of data collection screening to ensure women 
wore the accelerometer device overnight. Our sample was reduced substantially by the 1,943 
women without sleep data and the 1059 women without biomarker data who were excluded from 
this analysis. It is likely that as health worsens and comorbidities increase with age, sleep 
duration and quality are impacted, as seen previously in longitudinal studies of sleep duration 
and incident CVD.11,33,55 Lastly, while we included sleep medications and sleep disturbance in 
our analysis, we were not able to include a diagnosis of obstructive sleep apnea (OSA). This was 
not assessed in the LLS questionnaire. Evidence demonstrates that OSA is a risk factor for many 
cardiometabolic conditions, including obesity, hypertension, insulin resistance, and CVD.56,57  
Not being able to eliminate this possible mediator is a limitation of this study.  However, 
previous evidence suggest that the bulk of OSA remains undiagnosed and untreated, particularly 
in the elderly, so we believe that our findings still have real world applicability. Finally, because 
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we employed hip accelerometers, which provide a valid assessment of total sleep duration, we 
were not able to examine aspects of sleep quality. Previous research suggests that sleep quality is 
also a possible risk factor for CVD.4 More research is need to examine objectively measured 
sleep quality and CVD risk in large diverse cohorts of older women.  
 The results of this study support the growing evidence that sleep duration is a potential 
modifiable risk factor for CVD. As the incidence of CVD continues to increase in the aging 
population of women in the United States, it is important to identify additional risk factors that 
can be targeted in order to enhance CVD prevention interventions. While the length of sleep for 
optimal health is not completely clear at present and may vary by individual, this study 
highlights the importance of sleep duration for cardiovascular health.  
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Figure 2.1: OPACH study participant flow diagram 
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Table 2.1: Participant characteristics for the OPACH cohort by quartiles of average nightly sleep 
duration 
 Overall Average Nightly Sleep Duration (hours/night) Trend, 
 
N=3369 
Mean ± SD 
N (%) 
<7 hours 
n=517 
7-8 hours 
n= 975 
8-9 hours 
n=1149 
>9 hours 
n=728 
P-
value 
Age, years 78.9 ± 6.7 77.6 ± 6.5 78.3 ± 6.6 79.4 ± 6.7 80.0 ± 6.8 <.01 
  63-69 334 (9.9) 67 (13.0) 110 (11.3) 100 (8.8) 57 (7.8) <.001 
  70-79 1295 (38.4) 234 (45.3) 391 (40.1) 416 (36.2) 254 (34.9)  
  80-89 1591 (47.2) 205 (39.7) 444 (45.5) 570 (49.6) 372 (51.1)  
  ≥90 149 (4.4) 11 (2.2) 30 (3.1) 63 (5.5) 45 (6.2)  
Race-ethnicity      <.001 
  White 1797 (53.3) 208 (40.2) 531 (54.5) 667 (58.1) 391 (53.7)  
  Black 1007 (29.9) 201 (38.9)  278 (28.5) 300 (26.1) 228 (31.3)  
  Hispanic 565 (16.8)  108 (20.9)  166 (17.0) 182 (15.8) 109 (15.0)  
Education      0.49 
  High school or less 694 (20.6) 98 (19.1) 202 (20.8) 228 (20.0) 166 (23.0)  
  Some college 1300 (38.6) 191 (37.2) 379 (39.0) 455 (39.8) 275 (38.1)  
  College graduate 1357 (40.3) 225 (43.8) 391 (40.2) 460 (40.2) 281 (38.9)  
Health Behaviors       
Alcohol Intake in past 3 
months 
≥5 drinks/wk 
 
 
362 (10.8) 
 
 
45 (9.4) 
 
 
121 (13.4) 
 
 
123 (11.6) 
 
 
73 (10.9) 
 
 
<0.05 
Physical Activity 
mins/day 
344.4 ± 97.7 384.1 ± 108 366.5 ± 92.7 338.0 ± 87.8 296.8 ± 90.3 <.001 
Sleep Disturbance Score 6.3 ± 4.5 5.8± 4.5 6.1 ± 4.3 6.3 ± 4.5 6.8 ± 4.6 <0.05 
Sleep Medication Use 
≥3 times/wk 
 
206 (6.1) 
 
21 (4.1) 
 
57 (5.9) 
 
69 (6.0) 
 
59 (8.1) 
 
<0.05 
Health Characteristics       
BMI, Kg/m2 27.9 ± 5.7 28.5 ± 5.8 28.0 ± 5.8 27.5 ± 5.5 27.7 ± 5.5 0.97 
  ≥30 (obese) 994 (29.5) 168 (32.7) 293 (30.2) 326 (28.6) 207 (28.7) 0.23 
Physical Functioning 
 0-100 score 
68.4 ± 25.8  70.7 ± 25.6 70.3 ± 25.0 69.4 ± 24.5 62.7 ± 28.0 <.001 
Comorbidity Index 
≥2 comorbidities 
610 (18.1) 79 (15.3) 149 (15.3) 213 (18.5) 169 (23.2) <.001 
Depression Score  
range 0-1 
0.03 ± 0.1  0.03 ± 0.1 0.03 ± 0.1 0.02 ± 0.1 0.03 ± 0.1 <0.05 
Self-report Health  
At least good 
 
2825 (83.9) 
 
449 (93.9) 
 
830 (92.1) 
 
964 (90.6) 
 
582 (86.7) 
 
<.001 
Reynolds Risk Score 
Components 
      
Total Cholesterol  
mg/dL 
197.3 ± 39.6 196.1 ± 39.8 196.5 ± 38.1 198.0 ± 40.4 198.2 ± 40.2 0.57 
HDL Cholesterol 
mg/dL 
60.8 ± 15.2 61.5 ± 14.8 60.5 ± 15.2 60.9 ± 15.0 60.3 ± 15.5 0.94 
Systolic Blood Pressure  125.6 ± 14.5 125.3 ± 13.9 125.9 ± 14.5 125.3 ± 14.7 125.8 ± 14.7 0.96 
High-sensitivity CRP 
mg/L 
3.6 ± 8.8 3.4 ± 5.0 3.2 ± 5.8  3.8 ± 12.1 4.1 ± 8.0 0.07 
History of diabetes  655 (19.4) 118 (22.8) 173 (17.7) 211 (18.4) 153 (21.0) 0.06 
Family History of CVD 308 (9.1) 38 (7.4) 95 (9.7) 103 (9.0) 72 (10.0) 0.40 
Current smoker 78 (2.3) 19 (3.7) 27 (2.8) 18 (1.6) 14 (1.9) <0.05 
BMI, body mass index; min, minutes. Note: Numbers to not sum to total due to missing data 
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Table 2.2: Estimated Reynolds risk score for sleep durations (N=3369) 
Sleep Duration  
Hours (mins) 
Estimated Reynolds Risk Score 
Model 1a Model 2b Model 3c 
5 Hours  
(300 mins) 
14.04 15.04 14.55 
6 Hours  
(360 mins) 
12.38 13.40 13.18 
7 Hours  
(420 mins) 
11.62 12.39 12.34 
8 Hours  
(480 mins) 
11.76 12.02 12.03 
9 Hours  
(540 mins) 
12.80 12.27 12.24 
10 Hours  
(600 mins) 
14.73 13.16 12.99 
11 Hours  
(660 mins) 
17.57 14.68 14.26 
p valued <0.001 <0.001 <0.01 
a Adjusted analyses include race/ethnicity and education 
b Adjusted analyses include race/ethnicity, education, alcohol intake, physical activity, sleep medications, and 
sleep disturbances 
c Adjusted analyses include race/ethnicity, education, alcohol intake, physical activity, sleep medications, 
sleep disturbances, BMI, physical functioning, comorbidities, depression, and self-rated health 
dp values presented for quadratic term in the model 
 
Figure 2.2: Sleep duration and Reynolds Risk Score in the OPACH 
sleep cohort after adjustment.1 
                                                 
1 Model adjusted for race/ethnicity and education 
Linear trend p= <0.001 
Non-linear trend p= <0.001 
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Figure 2.3: Sleep duration and Reynolds Risk Score in the OPACH 
sleep cohort after further adjustment.2 
 
Figure 2.4: Sleep duration and Reynolds Risk Score in the OPACH sleep cohort after final 
adjustment.3  
                                                 
2 Model adjusted for race/ethnicity, education, alcohol use, sleep medications, sleep disturbances, and total minutes 
of accelerometer measured physical activity 
3 Model adjusted for race/ethnicity, education, alcohol use, total minutes of accelerometer measured physical 
activity, sleep medications, sleep disturbances, BMI, physical functioning, comorbidity index score, depression, and 
self-rated health. 
Linear trend p= <0.001 
Non-linear trend p=<0.001 
Linear trend p= <0.01 
Non-linear trend p=<0.01 
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CHAPTER 3 
Accelerometer-Measured Sleep Duration and Cardiovascular Incidence in Post-
Menopausal Older Women: Evidence from the Women’s Health Initiative 
ABSTRACT 
 Background: Epidemiological studies have found an increased risk of incident CVD for 
self-reported short sleep duration or self-reported long sleep duration when compared to sleep 
durations of 8-9 hours. To advance the understanding of the relationship between sleep duration 
and CVD, there is a need for more research to examine the relationship between sensor-
measured sleep duration and CVD risk in an older population of women, and to determine if 
insufficient sleep duration is a CVD risk factor that holds promise for future CVD prevention 
strategies. 
 Methods: Participants from the Women’s Health Initiative OPACH Study (n=4203, 
mean age=78.5, 33.4% Black, 17.0% Hispanic) wore accelerometers on the hip for up to 7 days, 
completed a daily sleep log, and were followed for incident CVD for up to 5 years. Sleep 
duration derived from accelerometer data was calculated using a visual inspection protocol. Self-
reported sleep duration was averaged from daily sleep logs. Cox proportional hazards models 
estimated hazard ratios (HR) and 95% confidence intervals (CIs) for both measures of sleep 
duration in relation to incident coronary heart disease (CHD) and incident CVD. Fully adjusted 
models included age, race-ethnicity, smoking, education, comorbidities, physical function, self-
rated health, and total physical activity. 
 Results: In minimally adjustment models, neither short or long sleep duration, measured 
by accelerometry, were associated with increased risk of CVD. In contrast, log-based long sleep 
duration (>9 hours/night) was associated with increased risk of CVD, in the model adjusted for 
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age, race-ethnicity, education, and smoking (HR: 1.27; CI:1.01,1.61). In the fully adjusted 
model, this association between log-based long sleep duration and CVD was no longer 
significant.  The mean difference in accelerometer-measured sleep duration and log-based self-
reported sleep duration was 18 minutes (SD:43.88 minutes) and physical functioning (B:-0.18, p: 
<0.001) and total minutes of PA (B:0.05, p: <0.001) were significantly associated with 
differences in sleep duration estimates. 
 Conclusions: After adjustment for demographics and markers of health status, neither 
short or long sleep durations were associated with an increased risk of CHD or CVD over the 5-
year period in this sample of older women. Future studies with multiple time points of sleep 
assessment and assessment of sleep disorders are necessary to explore further the relationship 
between sleep and CVD risk.  
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INTRODUCTION 
 Over half of older adults in the United States experience disturbed sleep,  including 
shorter or longer sleep durations, increased frequency of awakenings, difficulty maintaining 
sleep, decreased sleep efficiency, and changes to sleep architecture.1–5 Older women are more 
likely to report sleep disturbances and poor sleep quality than their male counterparts.1,3,5 In a 
Women’s Health Initiative (WHI) study examining sleep disturbances in over 98,000 older 
women, weekly night time awakenings and daytime sleepiness were reported by over 75% of the 
women in the study.6 The large proportion of older adult women who regularly experience poor 
or insufficient sleep may be at risk of adverse health outcomes and pose a major public health 
concern.7  
 Emerging evidence suggests that sleep duration may be a cardiovascular disease (CVD) 
risk factor.8,9 The American Heart Association estimates that more than one in three US women 
has some form of CVD, and an additional 90% of women are currently living with one or more 
risk factors.10 As women age, their risk of cardiovascular disease (CVD) increases. Older women 
over the age of 80 years are at greatest risk for CVD, with higher incidence of CVD events than 
men of the same age.11 Recent studies have focused on the cardiometabolic associations of sleep 
quality and sleep duration, including a number of cross-sectional and prospective studies 
demonstrating that self-reported short and long sleep durations are predictors of incident 
cardiometabolic conditions such as: type 2 diabetes, hypertension, metabolic syndrome, and 
obesity.12–17 Further, prospective epidemiological studies have found an increased risk between 
30-50% of incident CVD for self-reported short sleep duration (<6 hours) or self-reported long 
sleep duration (>9 hours) when compared to sleep durations of 8-9 hours.18–22 Reviews of the 
existing research, based on self-reported measures, have concluded that inadequate sleep 
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duration and poor sleep quality are associated with increased development, progression, and 
severity of CVD and CVD comorbidities.9 
 Our understanding of the relationship between sleep duration and CVD remains 
incomplete due to the limitations of the existing research. Previous studies have consisted 
primarily of cross-sectional study designs, or have been limited in the reliance on one-item self-
reported measures of sleep duration.23,24 Studies have demonstrated that when sleep duration is 
assessed by one survey item asking participants to recall their “usual” sleep, it is significantly 
overestimating sleep duration when compared to wrist actigraphy.25,26 Monitoring sleep duration 
through body-worn sensors, e.g. accelerometers, is considered more accurate than self-reported 
sleep duration or sleep logs alone,27 especially in older adult populations where cognitive issues 
affecting recall may be present.28  Another weakness of previous studies includes samples 
primarily consisting of middle-aged non-Hispanic white adults. While CVD incidence is higher 
in older women, and African American and Non-white Hispanic populations,11 most published 
studies on sleep and CVD risk have not adequately represented women from these groups.8,9 The 
2016 scientific statement from the American Heart Association on sleep and cardiometabolic 
health urges future research to include both women and minorities in study samples and for more 
objective measurements of sleep.8  
 The objective of the current study was to prospectively examine associations of sleep 
duration, measured by self-reported sleep log and accelerometry, with incident CHD and CVD 
events over up to 5 years of follow-up in a racial-ethnically diverse cohort of older women. We 
postulated, a u-shaped relationship between sleep duration and CVD events, with fewer hours of 
sleep and excess hours of sleep being associated with an increased risk of CVD.  
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METHODS 
Study Population 
 The Women’s Health Initiative (WHI) is a national study focusing on healthy aging, 
morbidity, and mortality among postmenopausal women that recruited women for participation 
in a Clinical Trial Program or an Observational Study from 1993-1998.  
 Women in the present study were enrolled for participation in the Objective Physical 
Activity and Cardiovascular Health (OPACH) study, a WHI ancillary study. The aims of the 
OPACH study were to examine prospectively the relationship between accelerometer-measured 
physical activity and incidence of CVD in older women. Details on OPACH recruitment and 
methodology have been previously published.30 
 Between 2012-2013, women participating in a WHI extension study, the Long Life Study 
(LLS), completed in home health assessments. During this visit, fasting blood draws, information 
regarding personal health and lifestyle, anthropometric measurements, and blood pressure were 
obtained. A subset of LLS participants (N=7048) were consented and enrolled in the OPACH 
study. OPACH participants received GT3x accelerometer devices and were asked to wear them 
on their waist for 24 hours per day over a 7-day period.  Additionally, participants were asked to 
complete sleep logs and report their in-bed time and out-of-bed time for the 7-day accelerometer 
wear period.  
 Of the 7048 women who were OPACH consented participants, 6,489 women returned 
their devices and provided at least one day of accelerometer data.  Of these, 4,204 met eligibility 
criteria for inclusion in this analysis, including completion of at least 3 nights of valid 
accelerometer data, and a completed sleep log (Figure 3.1). Participants with fewer than 3 nights 
of accelerometry data, or those who were missing a completed sleep log were excluded from this 
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analysis. Women with an myocardial infarction (MI) or stroke before OPACH baseline (n=520) 
were also excluded. In consideration of night to night sleep variation, previous sleep studies have 
demonstrated that one night of accelerometer wear is not sufficient to assess regular sleep 
habits.31 Additionally, previous cohort studies examining cardiovascular health have defined 
valid wear as three nights.32  
Coronary Heart Disease and Cardiovascular Disease Events 
 The primary endpoint was defined as a major fatal or non-fatal CVD event including 
incident coronary heart disease (CHD), including MI or coronary death, or new CVD event 
including hospitalized angina, coronary artery bypass graft (CABG), congestive heart failure, 
revascularization, percutaneous transluminal coronary angioplasty (PTCA), stroke, or fatal CVD 
event. These events were combined to examine the associations of sleep duration with incident 
CHD and CVD. Adjudicated incident CVD outcomes were initially identified through annual 
follow-up contacts and then verified by trained staff through medical records and death 
certificates. The WHI protocol for outcome diagnosis and adjudication have been previously 
described.33  Participants were followed for first occurrence of a CVD outcome, and those 
individuals who did not develop CVD were censored at the date of death or last contact.  
Log-Based Sleep Duration 
 Self-reported sleep duration was assessed with a participant sleep log. Participants were 
asked to complete a daily sleep log during the 7-day accelerometer wear period, to record their 
time into bed for the night and time out of bed in the morning for each night. Sleep logs were 
returned in the mail with the accelerometer device. A nightly sleep duration (total minutes) was 
calculated as the total amount of time in bed the participant reported. Mean sleep duration was 
calculated across the available nights of self-reported sleep duration (ranging from 3-7 nights) to 
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create an average nightly self-reported sleep duration variable. The log-based sleep duration was 
selected for this analysis over a 1-item self-report measure of usual sleep duration as the 7-day 
sleep logs provide real time self-reported information over the same 7 days as the accelerometer 
measured sleep duration. Validation studies have shown that a 1-item survey measure and 1-
week sleep log have a .79 correlation.     
Accelerometer Measured Sleep Duration 
 Accelerometer measured sleep duration was assessed with the hip-worn triaxial 
accelerometer (Actigraph GT3X+; Pensacola, FL). Participants wore the accelerometer device on 
their hip, 24 hours a day for 7 consecutive days, except for time spent bathing or swimming. 
Data were recorded in 1-second epochs collected at a frequency of 30 Hertz. Wrist-worn 
accelerometer devices are more standard for sleep assessment, however hip-worn accelerometers 
are the norm for physical activity studies like OPACH.34,35 Hip accelerometers have been shown 
to provide valid assessments of total sleep duration against the gold standard 
polysomnography.35,36  
 Upon device return, raw data were processed using ActiLife version 6.11 software. Raw 
data were condensed to 60 second AGD files. AGD files were scored for sleep variables using a 
standard visual inspection protocol. For each night of wear, a trained member of the research 
team identified the primary sleep window using the participant reported in-bed and out of bed 
time from sleep logs and visual review of the data. This procedure is adapted for hip devices 
from a protocol shown previously to have high inter-rater reliability.37 The validated Cole-
Kripke algorithm38 was applied to classify each minute of the sleep interval as sleep or wake. 
Estimates of nightly sleep duration were derived as the total amount of time classified as sleep 
(minutes/night) during the primary sleep period. Mean sleep duration was calculated across the 
 90 
available nights of scored sleep (ranging from 3-7 nights) to create an average nightly sleep 
duration variable.  
 
Covariates 
 WHI questionnaires were used to obtain information on participant demographics, 
education, smoking, self-reported physical functioning, self-rated health, depressive symptoms, 
self-reported sleep disturbances, and history of chronic conditions.  
 Education was categorized into 3 levels: high school or less, some college, college 
graduate or more. Smoking was measured with 1-item assessing if the participant is a current 
smoker, response options were “yes” or “no”. Physical functioning was assessed using the 10-
item physical function score of the RAND 36-item health survey.39 The physical function score 
has a range of 0-100 with higher scores indicating better function. Self-rated health was assessed 
with 1-item from the WHI lifestyle questionnaire asking participants “In general would you say 
your health is…”. Response options ranged on a 5-point scale from “excellent” to “poor”. 
Depression was assessed with the WHI Burham adaptation Scale,40 of the CES-D scale. Scale 
scores ranged from 0-1 with higher values indicating a higher presence of depressive symptoms. 
Sleep disturbances were assessed with the WHI Insomnia Rating Scale (WHIIRS).41 A scale 
score is calculated from the five item scores (0-4) to create a global sleep disturbance score 
ranging from 0-20. A higher WHIIRS score is reflective of greater presence of sleep disturbances 
and has been shown to be predictive of CVD.24 The use of sleep medications was assessed with 
1-item assessing in the last 4 months, how many times per week a participant used sleep 
medications. Response options ranged from “None in the past 4 weeks” to “5 or more times per 
week”. A comorbidity index variable was created using the self-report of chronic conditions 
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collected in the baseline survey. The index included self-report of history of chronic obstructive 
pulmonary disease (COPD), history of osteoarthritis, history of cerebrovascular disease, history 
of cancer, history of cognitive impairment, and history of hip fractures. The number of 
conditions was summed to create a comorbidity index score (0-6).  
 The Reynolds Risk Score (RRS), is calculated using age, systolic blood pressure (SBP), 
high-sensitivity C-reactive protein (CRP), total and HDL cholesterol, diabetes mellitus status, 
smoking status, and family history of premature myocardial infarction. The score is calculated as 
an estimate for 10-year predicted CVD risk.42 At the LLS home visit, fasting blood measures 
used in the RRS calculation (including CRP, total cholesterol, and HDL cholesterol) were 
obtained. Resting blood pressure (BP) was measured after a 5-minute rest period using an 
aneroid sphygmomanometer and cuff size based on measured arm circumference.  Diabetes 
mellitus status, smoking status, and family history of premature myocardial infarction were 
assessed using the LLS questionnaire. Total daily physical activity minutes were calculated from 
the GT3x accelerometer when summed vector magnitude counts exceeded 8 counts per 15 
seconds.43 
 
Statistical Analysis 
 Survival analyses were completed to assess the association between baseline sleep 
duration and incident CHD events and new CVD events using Cox proportional hazard 
regressions. Both log-based and accelerometer-measured sleep durations were examined 
categorically, as short sleep (<8 hours) and long sleep (>8 hours) compared to healthy sleep (8-9 
hours).  These categories were selected based on the distribution of sleep duration in the cohort. 
A series of progressive adjustment models were evaluated in the analysis: the first minimally 
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adjusted for age and race-ethnicity, the second added adjustment for education and smoking, the 
third added adjustment for self-rated health, comorbidities, and physical functioning, and the 
final model added an additional adjustment for total minutes of physical activity. Secondary 
models added adjustment for self-reported sleep disturbances and depression. There was no 
multi-collinearity between independent variables in the models.  
 Sensitivity analyses were conducted to determine if how the sleep duration categories 
were defined impacted the results of the hazard ratio models. In these additional analyses short 
sleep was defined as either <7 hours/night and <6 hours/night and long sleep defined as >9 
hours/night. Participants who averaged 7-8 or 8-9 hours/night served as the reference category. 
Further stratified analyses were conducted (stratified by RRS, total minutes of MVPA, and 
physical functioning) to assess possible confounders and to see if the relationships examined in 
the cox proportional hazard analyses remained consistent.  
 The difference in log-based sleep duration and accelerometer-measured sleep duration 
was calculated. Linear models adjusted for age and race-ethnicity were used to explore the 
possible predictors of the discordance in the measures. 
RESULTS 
 The mean age of the 4204 women was 78.5 years (range 63-99; Table 3.1). Overall, 
49.5% of women were white, 33.4% black, and 17% Hispanic. The majority of women had at 
least some college education (79.5%). Women had a mean BMI of 28.0 kg/m2.  On average, 
women reported a sleep disturbance score of 6.27, out of 20. The average physical functioning 
score was 69.6 and 13.9% of the sample reported 2 or more comorbid conditions. Only 2% of the 
women reported current smoking. 
Sleep Duration and Baseline Characteristics 
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 When measured by sleep log, 35% of women in the cohort self-reported sleep durations 
between 8-9 hours, while only 32% had accelerometer-measured sleep durations between 8-9 
hours. The proportion of women with log-based long sleep durations (>9 hours) was greater than 
the proportion of women with accelerometer-measured long sleep durations (30% vs 23%). For 
both measures of sleep duration, long sleepers (>9 hours) were more likely to be older women 
with a mean age of 79.4 years, and were more likely to be white women (47.9% for log-based, 
50% for accelerometer measured) compared to women who had short sleep durations (mean age: 
77.7 years; proportion white: 44% for log-based and accelerometer measured). Long sleepers 
also had the lowest levels of total daily physical activity (mean minutes: 307.5 for log-based, 
296.3 for accelerometer measured), highest sleep disturbance scores (mean: 6.7 for log-based, 
6.8 for accelerometer measured), and the lowest physical functioning scores (mean: 63.2 for log-
based, 62.7 for accelerometer measured) compared to women in the short or healthy (8-9 hours) 
sleep duration categories. Across both measures short sleepers (<8 hours) were more likely to 
report excellent self-rated health (55.2% for log-based, 53.9% for accelerometer-measured), and 
more likely to be current smokers (3.2% for log-based, 2.9% for accelerometer-measured) 
compared to women with healthy sleep durations (self-rated health: 54.7% for log-based, 53.3% 
for accelerometer-measured; smokers: 1.5% for log-based, 1.9% for accelerometer-measured).   
On average, participants log-based sleep durations were 18 minutes longer (SD:43.88 
minutes, range: 0-359 minutes) than their accelerometer-measured sleep duration. The two 
measures appear to estimate sleep duration similarly and were positively correlated with a 
Pearson’s correlation of r=0.83 (p=<0.001; Figure 3.2). In the linear model adjusted for age and 
race/ethnicity, physical functioning scores (B:-0.18, p: <0.001) and total minutes of PA (B:0.05, 
p: <0.001) were significantly associated with the difference in sleep duration estimates, 
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indicating that women with lower physical functioning scores and higher total minutes of PA had 
greater differences between their sleep duration estimates. 
Sleep Duration and incident CHD and new CVD events 
Within an average follow-up period of 3.5 years (range 0.01 – 4.91 years), a total of 143 
incident cases of CHD (MI or coronary death) and 536 CVD events occurred. For log-based 
sleep duration, after adjustment for age and race/ethnicity, the risk of incident CVD was 
significantly higher for women in the long sleep category (>9 hours) [Hazard Ratio (HR): 1.27, 
95% confidence interval (CI): 1.01,1.61], compared with women in the healthy sleep category 
(8-9 hours), but did not differ significantly for women in the short sleep category (<8 hours; 
Table 3.2). These results remained consistent after adjustments for education and smoking. 
When further adjusted for comorbid conditions, physical functioning, and self-rated health the 
risk of CVD was no longer significantly higher for women in the long sleep category when 
compared to women in the healthy sleep category [HR: 1.13, CI: 0.89,1.43]. The increased risk 
of incident CHD after adjustment for age and race/ethnicity was not significant for long sleepers 
[HR: 1.37, CI: 0.87-2.16] or for short sleepers [HR: 1.11; CI: 0.69-1.80] when compared with 
women with log-based sleep duration in the 8-9 hour category. Additional adjustment for sleep 
disturbances produced similar results.  
For accelerometer-measured sleep duration, after adjustment for age and race/ethnicity, 
risk of incident CVD was similar for women in the long sleep category (>9 hours, HR:1.08; 
CI:0.84-1.80) or the short sleep category (<8 hours, HR: 1.06; CI:0.85-1.33) as compared to 
women in the healthy sleep category (8-9 hours). These results remained null after additional 
adjustment for education, smoking, comorbid conditions, physical functioning, self-rated health 
and sleep disturbances. For CHD, after adjustment for age and race-ethnicity there was no 
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significant increased risk for women with accelerometer-measured long sleep duration [HR: 
0.80, CI: 0.52-1.21] or women with short sleep duration [HR: 0.76; CI: 0.46-1.21] when 
compared with women with sleep duration in the 8-9 hour category. 
 Sensitivity analyses showed that, the multivariable-adjusted associations for both log-
based sleep durations and accelerometer-measured sleep durations were similar to the results of 
the primary analysis when sleep was categorized with short sleep defined as <6 or <7 hours, and 
long sleep as >9 hours. To further evaluate the influence of health status at baseline, we stratified 
these associations according to median RRS, median total PA, and median physical functioning.  
The results of the stratified analyses were similar to the primary analyses for the RRS median 
split (log-based: p-trend=0.2; accelerometer measured: p-trend=0.6) and median total PA split 
models (log-based: p-trend=0.2; accelerometer measured: p-trend=0.8). When the log-based 
sleep duration analyses were stratified by physical functioning, in the low physical functioning 
group the risk of incident CVD was significantly higher for women in the long sleep category 
(>9 hours, HR: 1.42; CI: 1.07-1.88 p-trend: 0.01], compared with women in the healthy sleep 
category (8-9 hours). For women in the high physical functioning group, neither short or long 
sleep was associated with increased risk of incident CVD.  
  
DISCUSSION 
 To our knowledge this is the first study to examine the relationship of accelerometer-
measured sleep duration and incident CVD in a cohort of older women. After adjustment for 
demographics and markers of health status, neither short or long sleep durations were associated 
with an increased risk of incident CHD or new CVD events. These results were consistent for 
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both self-reported log-based sleep duration and accelerometer-measured sleep duration after a 
series of progressive adjustments. 
 Previous studies have shown associations between one-item self-reported short and long 
sleep duration and increased risk for cardiometabolic conditions that are risk factors for CVD, 
including: incident type 2 diabetes, obesity, and metabolic syndrome.13,14,17,44 The relationship 
between one-item self-reported sleep duration and incident CVD and CHD has been examined in 
several studies with more varied results, with some studies showing increased risk for both short 
and long sleep durations, and some studies showing no increased risk across sleep 
durations.18,24,45 In the OPACH cohort, short sleep durations (<6, <7,  or <8 hours), measured 
either by sleep log or accelerometer, were not related to increased risk of CVD. The difference in 
our results could be attributed to the age of the cohort and the overall longer sleep durations 
observed. In our analysis, women with shorter sleep durations were younger, and appeared to be 
overall healthier, with better self-reported health, higher physical functioning, and higher total 
PA than women in the 8-9 hours/night or >9 hours/night categories.  
 The lack of association of log-based sleep duration with incident CHD and new CVD 
events in this study are consistent with a previous WHI study examining survey-reported sleep 
duration and CVD incidence in older women. Among 86,329 women between the ages of 50 and 
79 years, a modest increase in risk was seen for short (<7 hours) and longer sleepers (>10 hours) 
in minimally adjusted models; however, the increase in risk was not significant after adjustment 
for socioeconomic status, lifestyle behaviors, and comorbid conditions.24 The authors suggested 
that in part the increase in risk was due to comorbid conditions in the population. In our analysis, 
self-reported long sleep duration was associated with increased risk when compared to sleep 
durations of 8-9 hours; however, this relationship was no longer significant after adjustments for 
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comorbid conditions. Further, this relationship was not found in any of the accelerometer-
measured sleep duration models. These results suggest that the increased CVD risk associated 
with self-reported long sleep duration may be attributed to poor health status and not sleep 
duration. Women who reported long sleep durations were older, had less total physical activity, 
lower physical functioning, higher sleep disturbances, more comorbid conditions, and were less 
likely to report excellent health. Further, when we explored predictors of the difference in the 
log-based self-report and accelerometer measured sleep, poorer physical functioning and higher 
physical activity were significantly related to an overestimation in sleep duration.  Previous 
research has suggested that how a participant reports sleep duration may be impacted by other 
factors including: socio-economic status, living conditions, other health behaviors, and overall 
health status.46  This difference in log-based sleep when compared to accelerometer-measured 
sleep, may be a reflection of the women’s overall health status, and not necessarily reflective of 
sleep duration. For older women, reporting longer periods in bed may not actually reflect time 
spent sleeping, but the presence of sleep disorders, such as obstructive sleep apnea, or comorbid 
conditions such as depression or mental health outcomes, which are all associated with longer 
sleep durations.47  
 While the study results do not support a relationship between sleep duration and incident 
CVD, they do not contradict the role that sleep plays in health. In our cohort, whether log-based 
or by accelerometer, long sleepers had overall poorer health status than individuals in the 8-9 
hour sleep category. Previous studies support that the relationship between sleep duration and 
health may be bi-directional, with poor sleep leading to poor health, and poor health leading to 
poor sleep.1,8,47 In this cohort of older women, while we may not be able to identify an optimal 
sleep duration associated with lower CVD incidence, we should still consider how sleep may 
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contribute to other health outcomes, including those that are in the pathway to CVD. A previous 
analysis completed in this cohort demonstrated that sleep duration, measured by accelerometer, 
was associated with markers of cardiometabolic health and 10-year estimated risk of CVD. In 
addition to the relationship between sleep duration and markers of cardiometabolic health, 
evidence demonstrates that sleep is related to other health behaviors that are associated with 
CVD risk, including diet, PA, and sedentary behavior.8,48 In the OPACH cohort, previous 
analyses have found that light PA was protective against incident CVD and high levels of 
sedentary behavior were associated with increased risk of incident CVD.49,50 It is possible in this 
cohort, as in previous studies, that these activities may be interrelated and that sleep duration is 
associated with daily PA and sedentary behavior.48,51,52  
 The present study has some limitations. Our study cohort included only older women 
over the age of 63 years, and therefore is not generalizable to the population as a whole. These 
women make up a unique subpopulation who are at increased risk for CVD, but who have also 
survived (mean age of 78.5 years) to later life. As discussed previously, health worsens with age 
as does sleep quality, therefore it is difficult to untangle this complex relationship. An 
assessment of sleep disorders, such as obstructive sleep apnea (OSA) was not included in our 
analysis as they were not assessed in the LLS questionnaire. Previous research suggests that 
OSA is a risk factor for CVD,53,54 and a possible confounder in the relationship between sleep 
duration and CVD.55 Without the assessment of sleep disorders, including OSA, we could not 
disentangle sleep duration with or without a concomitant sleep diagnosis. However, given the 
null results observed in this investigation, confounding by OSA seems unlikely. Finally, because 
we employed hip accelerometers, valid for total sleep duration only, we were not able to examine 
aspects of sleep quality, beyond self-reported sleep quality. It is important to note that previous 
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studies have found that hip accelerometers do provide longer estimates of sleep duration than 
both PSG and wrist-worn accelerometers.56 Future research is needed to confirm these results, 
examining sleep duration and quality, assessed by wrist actigraphy or polysomnography, and 
CVD risk in large diverse cohorts of older women.  
In summary, this analysis contributes to the existing literature by examining sleep 
duration, measured both by sleep logs and accelerometers in the same cohort of women, and 
incident CVD. After adjustment for age, race-ethnicity and health status, neither women with 
short sleep or long sleep durations had an increased risk of CVD, compared to women with sleep 
durations between 8-9 hours. The increased risk that was seen for women with long self-reported 
sleep duration in the minimally adjusted models may be explained by other markers of poor 
health status, including physical functioning or lower levels of total PA. Future studies with 
multiple time points of sleep assessment and assessment of sleep disorders are necessary to 
explore further the relationship between sleep and CVD risk.  
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Table 3.1: Participant characteristics for the OPACH cohort by measure sleep duration category 
 
Overall 
Sample 
Log-Based Sleep Duration Accelerometer Sleep Duration 
 
N=4204 
mean ± 
SD n 
(%) 
<8 hours 
n=1428 
8-9 
hours 
n=1476 
>9 
hours 
n=1299 
<8 hours 
n=1857 
8-9 hours 
n=1373 
>9 hours 
n=974 
Age, years 
78.5 ± 
6.8 
77.7 ± 
6.6 
78.5 ± 
6.8 
79.4 ± 
6.7 
77.7 ± 
6.6 
78.9 ± 
6.8 
79.4 ± 
6.8 
  63-69 
469 
(11.2) 
189 
(13.2) 
174 
(11.8) 
106 (8.2) 
240 
(12.9) 
144 
(10.5) 
85 (8.7) 
  70-79 
1693 
(40.3) 
612 
(42.9) 
575 
(39.0) 
506 
(39.0) 
808 
(43.5) 
524 
(38.2) 
361 
(37.1) 
  80-89 
1873 
(44.6) 
590 
(41.3) 
669 
(45.3) 
613 
(47.2) 
760 
(40.9) 
638 
(46.5) 
473 
(48.8) 
  ≥90 169 (4.0) 37 (2.6) 58 (3.9) 74 (5.7) 49  (2.6) 67 (4.9) 53 (5.4) 
Race-ethnicity        
  White 
2083 
(49.5) 
662 
(46.4) 
798 
(54.1) 
622 
(47.9) 
856 
(46.1) 
740 
(53.9) 
487 
(50.0) 
  Black 
1405 
(33.4) 
505 
(35.4) 
424 
(28.7) 
476 
(36.6) 
675 
(36.3) 
393 
(28.6) 
337 
(34.6) 
  Hispanic 
716 
(17.0) 
261 
(18.3) 
254 
(17.2) 
201 
(15.5) 
326 
(17.6) 
240 
(17.5) 
150 
(15.4) 
Education        
  High school or 
less 
841 
(20.0) 
279 
(19.6) 
268 
(18.3) 
293 
(22.8) 
365 
(19.8) 
263 
(19.3) 
213 
(22.0) 
  Some college 
1646 
(39.2) 
521 
(36.6) 
609 
(41.5) 
516 
(40.1) 
704 
(38.1) 
549 
(40.2) 
393 
(40.7) 
  College 
graduate 
1693 
(40.3) 
625 
(43.9) 
590 
(40.2) 
478 
(37.1) 
779 
(42.2) 
554 
(40.6) 
360 
(37.3) 
Health 
Characteristics 
 
    
 
 
Physical 
Activity 
(mins/day) 
344.2 
(98.4) 
374.8 ± 
102.8 
346.9 ± 
88.4 
307.5 ± 
92 
373.4 ± 
99.1 
338.6 ± 
87.8 
296.3 ± 
90.9 
Sleep 
Disturbances 
6.27 ± 
4.48 
5.8 ± 4.4 6.3 ± 4.4 6.7 ± 4.6 6.0 ± 4.4 6.3 ± 4.4 6.8 ± 4.7 
BMI (Kg/m2) 
28.0 ± 
5.7 
28.1 ± 
5.7 
27.8 ± 
5.5 
28.3 ± 
6.0 
28.3 ± 
5.8 
27.7 ± 
5.5 
28.0 ± 
5.8 
Physical 
Functioning 
(0-100) 
69.6 ± 
25.7 
72.8 ± 
24.5 
72.0 ± 
24.0 
63.2 ± 
27.7 
72.0 ± 
24.8 
71.1 ± 
24.3 
62.7 ± 
28.1 
Comorbidity 
Index (≥2 
conditions) 
584 
(13.9) 
170 
(11.9) 
211 
(14.3) 
203 
(15.6) 
228 
(12.3) 
191 
(13.9) 
165 
(16.9) 
Depression 
Score (0-1) 
0.03 ± 
0.1 
0.03 ± 
0.1  
0.02 ± 
0.1 
0.03 ± 
0.1 
0.03 ± 
0.1 
0.02 ± 
0.1 
0.03 ± 
0.1 
Self-rated 
Health  
       
Excellent 
2154 
(51.2) 
786 
(55.2) 
805 
(54.7) 
563 
(43.5) 
997 
(53.9) 
730 
(53.3) 
427 
(44.1) 
Good 
1666 
(39.6) 
552 
(38.8) 
554 
(37.7) 
560 
(43.3) 
736 
(39.8) 
519 
(37.9) 
411 
(42.4) 
Poor 369 (8.8) 86 (6.0) 112 (7.6) 
170 
(13.1) 
118 (6.4) 120 (8.8) 
131 
(13.5) 
Current 
smoker 
101 (2.4) 46 (3.2) 22 (1.5) 33 (2.5) 54 (2.9) 26 (1.9) 21 (2.2) 
Reynolds Risk 
Score1 
12.3 ± 
10.6 
11.3 ± 
10.0 
11.8 ± 
10.1 
14.0 ± 
11.7 
11.5 ± 
9.8 
12.2 ± 
10.4 
14.0 ± 
12.1 
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Table 3.2: HRs for log-based and accelerometer measured sleep duration and incident CVD  
Sleep Duration 
Category 
Median 
Sleep 
Duration 
(hours/night) 
Model 1 
HR 
(95% CI)a 
Model 2 HR 
(95% CI)b 
Model 3 
HR 
(95% CI)c 
Model 4 HR 
(95% CI)d 
Log-based sleep duration 
8-9 hours 8.47 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
short sleep 
(<8 hours) 
7.40 
1.07 
(0.84, 1.37) 
1.07  
(0.84, 1.37) 
1.08 
(0.85,1.38) 
1.12  
(0.88, 1.43) 
long sleep  
(>9 hours) 
9.65 
1.27  
(1.01-1.61) 
1.27  
(1.01-1.61) 
1.13 
(0.89,1.43) 
1.05  
(0.83, 1.34) 
Accelerometer sleep duration 
8-9 hours 8.44 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref) 
short sleep  
(<8 hours) 
7.29 
1.06  
(0.85, 1.33) 
1.05  
(0.84, 1.32) 
1.07  
(0.85, 1.34) 
1.13  
(0.90, 1.42) 
long sleep  
(>9 hours) 
9.60 
1.08  
(0.84, 1.40) 
1.07  
(0.83, 1.39) 
0.95  
(0.73, 1.23) 
0.87  
(0.67, 1.13) 
Ref, reference category 
a  Model 1 adjusted for race/ethnicity and age 
b Model 2 adjusted for race/ethnicity, age, education, and smoking 
c  Model 3 adjusted for race/ethnicity, age, education, smoking, comorbid conditions,  physical functioning,  
and self-rated health  
d Model 4 adjusted for race/ethnicity, age, education, smoking, physical functioning, comorbid conditions, self-
rated health, and total minutes of PA 
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DISCUSSION 
 Cardiovascular Disease (CVD) is the most prevalent chronic disease in the aging 
population.1 Despite the overall reduction in deaths in the last two decades, CVD is still a 
significant public health problem, especially for women. There is growing evidence supporting 
sleep duration as a risk factor for CVD in older women, however there remains gaps in the 
literature. This dissertation was designed to build upon and advance the existing research on 
sleep and cardiovascular health in older women. Employing accelerometer-measured sleep 
duration collected in a large and diverse cohort of older women, this dissertation contributes new 
scientific evidence with more accurate measurement in new population groups. In this 
dissertation, accelerometer-measured sleep duration was examined in relationship to markers of 
cardiometabolic health, 10-year estimated risk of CVD, and CVD events. This comprehensive 
approach advances the understanding of the role that sleep duration plays in the development of 
CVD.  
 Three overarching themes emerged from this work. (1) There is a clear non-linear 
relationship between sleep duration and cardiometabolic outcomes which has not been 
thoroughly examined previously. Both short and long sleep durations were associated with 
higher values of several cardiometabolic markers and with higher 10-year estimated CVD risk. 
(2) In older women, there is a difference between log-based self-reported and accelerometer-
measured sleep duration. It appears that self-reported sleep duration may be a measure of overall 
health status, calling into question previous evidence. (3) When examining sleep and 
cardiometabolic health, it is important to consider the interrelationship of sleep and other 
behaviors in the 24-hour day; most previous CVD studies in adults have not included sleep in 
analyses. 
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Sleep Duration and Associations with Cardiovascular Risk Factors 
 Chapter 1, entitled Modeling the cardiometabolic benefits of sleep in older women: 
exploring the 24-hour day, assessed the independent associations of accelerometer-measured 
sleep duration and markers of cardiometabolic health. In the series of cross-sectional analyses, 
the relationship between sleep and cardiometabolic outcomes appeared to differ across different 
markers, with a linear relationship for insulin, HOMA-IR, total cholesterol, and triglycerides and 
a u-shaped relationship with CRP, glucose, and waist circumference. This analysis included 
adjustment for age, race/ethnicity, and known covariates. These study results are consistent with 
previous single behavior analyses and meta-analyses demonstrating that accelerometer-measured 
sleep duration is related to several markers of cardiometabolic health including measures of 
metabolic function, gluco-regulatory function, and systemic inflammation.2–5 Of note, in our 
sample was there was no significant relationship found between sleep duration and BMI. 
Previous results have been mixed on the relationship between sleep duration and BMI, with 
some studies suggesting a u-shaped relationship and others finding no significant association.6–8 
Previous authors have suggested conflicting results may be due to differences in the ages of 
samples, which may also explain the difference found in the results in this cohort.2 While we did 
not find a relationship between sleep duration and BMI, there was a significant non-linear 
relationship between sleep duration and waist circumference in our sample, which is another 
measure of body composition. Additionally, the relationship between sleep duration and systolic 
blood pressure was not significant in our analysis. Previous studies have found a significant 
relationship between sleep duration and hypertension, however it has been suggested that this 
relationship may be modified by age, which may explain why we did not find a significant 
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association in this sample of older women.2,5,9,10 Further, many women in this sample are already 
medicated for hypertension and therefore it is difficult to adequately explore this relationship. By 
including a range of cardiometabolic markers and accelerometer-measured sleep duration from a 
large cohort of older women, these analyses provide a more comprehensive view of the 
relationship between sleep duration and cardiometabolic health in older women than has been 
previously examined. Additionally, this is one of the first studies to provide evidence of the U-
shaped relationship between sleep duration and cardiometabolic markers in older women using 
accelerometer-measured sleep duration.  
 While examining CVD risk factors individually with cross-sectional analyses may 
explain the immediate relationship between sleep and cardiometabolic health it may not explain 
the relationship between sleep and overall CVD risk. Chapter 2 - Association between 
accelerometer-measured sleep duration and clinical cardiovascular risk factor scores in older 
women - built on the analyses in Chapter 1 and demonstrated that sleep duration was non-linearly 
associated with 10-year estimated CVD risk among older women. The chapter details how both 
short and long sleep duration was associated with higher 10-year CVD risk, estimated by a 
clinically relevant composite risk score, and the shape of the relationship was explored. After 
several adjustments, the non-linear shape persisted. This study is one of the largest studies to 
provide additional evidence that sleep duration, measured with accelerometry, is non-linearly 
associated with a measure of CVD risk in older women. To our knowledge this study provides 
new evidence on the shape of the relationship between sleep duration and estimated CVD risk, 
with the use of accelerometry and a clinically relevant risk factor score.  
Sleep Duration and Incident CVD 
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 To advance the scientific field and determine if sleep duration is a risk factor for CVD, 
prospective studies that relate sensor-measured sleep duration with the incidence of CVD events 
are needed to clarify and build upon previous findings. In Chapter 3, Accelerometer-measured 
sleep duration and cardiovascular incidence in post-menopausal older women: Evidence from 
the Women’s Health Initiative the relationship between cardiovascular events over 3-5 years of 
follow-up and sleep duration was examined. This is one of the first prospective studies to 
examine the association between accelerometer-measured sleep duration and incident CVD in 
older women. The chapter details that neither short nor long sleep duration was associated with 
an increased risk of CVD over the 3 to 5-year period. These results were consistent between both 
log-based sleep duration and accelerometer-measured sleep duration, across several categories of 
short and long sleep duration. In addition to filling the gap in the evidence, this chapter provides 
further examination of the differences between a measure of self-reported sleep duration and 
accelerometer-measured sleep duration. Exploratory models found that the difference in sleep 
duration estimates was significantly related to the participant’s physical functioning scores and 
total minutes of physical activity (PA). This difference in self-reported sleep duration, and the 
longer sleep durations reported by women, when compared to accelerometer estimates, may be a 
reflection of the women’s overall health status, including both physical and mental health, and 
not necessarily reflective of their sleep. The findings of this chapter suggest that sleep duration 
may not be an independent risk factor for CVD. The previous longitudinal studies that found 
sleep duration, short or long, was independently associated with an increased risk of CVD events 
and CVD mortality were all based on self-reported estimates of sleep duration.11–19 The 
differences found between log-based and accelerometer-measured sleep duration in our sample 
proposes doubt in the previous evidence based on self-report. To our knowledge, there have been 
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no studies that have shown sleep duration, measured with accelerometry or actigraphy, is an 
independent risk factor for CVD. The results of this chapter support the need for future studies 
that include multiple time points of sleep duration, measured either by polysomnography or 
actigraphy, as well as the assessment of sleep disorders, to adequately explore the relationship 
between sleep duration and CVD risk in older women. 
Sleep Duration and the 24-Hour Day 
 In this dissertation, we learned that sleep duration was related to markers of 
cardiometabolic health and intermediate CVD risk, but that sleep duration did not independently 
predict incident CVD.  These findings may be explained by the interdependence of 24-hour 
activities, including sleep duration, PA and sedentary behavior, and their relationship to 
cardiometabolic health. This consideration of 24-hour activity is an important step in advancing 
the science and the understanding of the relationship between sleep duration and CVD.  
 This dissertation provides evidence that accelerometer-measured sleep duration is related 
to cardiometabolic health. We also know that sedentary behavior (SB) and PA, two other 
behaviors that make up the 24-hour day, are related to cardiometabolic health. Emerging 
evidence also demonstrates that sleep is related to these other behaviors that are associated with 
CVD risk.20 Within the OPACH cohort, previous analyses have found that light PA (LIPA) was 
protective against incident CVD, and higher levels of SB were associated with increased risk of 
incident CVD.21,22 These various analyses in the OPACH cohort provide evidence of how 24-
hour activities are interrelated. This dissertation is consistent with previous research 
demonstrating that sleep duration is associated with daily PA and SB, which are related to CVD 
risk.23–25 Moving forward, we must consider that, even after statistical adjustments, 24-hour 
activities are not independently related to cardiometabolic health and CVD risk. While we can 
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continue to study these behaviors in isolation, it will be difficult to untangle the interrelated 
effects they have on cardiometabolic health. The 24-hour day is comprised of a combination of 
activities that are both harmful and beneficial to cardiometabolic health. Each additional minute 
of MVPA is good for our health. Each additional hour of SB is bad for our health. Increasing or 
decreasing time spent in one behavior results in an increase or decrease in time spent in another 
behavior. All of these daily activities are bounded by the 24-hour day.26–28 Therefore, the 
behaviors throughout the 24-hour day are interdependent, and we must take this into 
consideration when we examine their relation to cardiometabolic health. In Chapter 1, the 
isotemporal substitution analysis was one method to assess the interrelationships of 24-hour 
activities. The chapter explored the use of the isotemporal models to examine the associated 
change in cardiometabolic risk of reallocating time spent sleeping; shifted to or from LIPA, 
moderate to vigorous PA (MVPA), or SB. While isotemporal modeling is not new, this is one of 
the first studies to use the approach with accelerometer-measured sleep duration and take into 
account the U-shaped relationship between sleep duration and cardiometabolic health. Our study 
results show that in long sleepers when time was reallocated from sleep to MVPA or LIPA it was 
associated with favorable cardiometabolic maker values. Further, when time was reallocated 
from SB to sleep in short sleepers it had beneficial associations with several cardiometabolic 
markers. This chapter suggests that cardiovascular interventions for older women should 
continue to target increasing LIPA and MVPA and reducing SB, but should also consider the 
role of sleep duration. For example, more time in bed not sleeping may not be beneficial, but 
reducing sleep time to add exercise in the morning could be advantageous. While the results of 
this dissertation do not support sleep duration as a risk factor for CVD, they do support sleep 
duration as a lifestyle behavior worth targeting for cardiometabolic risk reduction. 
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FUTURE DIRECTIONS 
 The composition of the day matters and activities throughout the 24-hour day are 
interdependent. Rather than continuing to examine LIPA, MVPA, SB, and sleep as independent 
and mutually exclusive categories, it may be worthwhile to shift our focus from individual 
behavior goals, to understanding 24-hour behavior profiles. Is there a composition of time spent 
in LIPA, MVPA, SB, and sleep that increases or decreases a women’s risk of CVD? The 
disparities in the high incidence and prevalence of CVD and CVD risk factors in groups of 
women highlight that current prevention strategies are not effective for these populations; there 
may be alternative combinations that are more feasible and effective. The majority of current 
CVD lifestyle interventions have targeted changing one behavior without considering the impact 
this will have on the other behaviors that make up the 24-hour day, including sleep. It is 
important we move beyond the paradigm of considering activities in isolation. It is exciting to 
think about the intervention design opportunities that come with changing our focus to 24-hour 
behavior profiles. We can design future cardiovascular lifestyle interventions with multiple 
behavior targets, including more specific activity replacement targets, or sequential behavior 
targets that include all 24-hour activities. Most importantly these interventions can be tailored, 
with behavior targets that are not only more feasible for older women, but may have greater 
benefits for their cardiometabolic health. While these interventions may be complex, this 
dissertation supports that sleep behavior is complex, as is each of the other activities throughout 
the 24-hour day. It does not serve us to continue to consider these 24-hour activities, including 
sleep, in isolation. Complex behaviors deserve more complex and thoughtful approaches to 
behavior change.  
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 Beyond expanding our thinking to develop new study designs and data collection 
methods that consider 24-hour assessment, we must also employ statistical methods and a larger 
framework that consider the composition of the 24-hour day in its relationship to health. In the 
current field of Public Health, sleep researchers, PA researchers, and SB researchers are often 
separate and conducting research independently. A 24-hour framework calls for the dilution of 
the boundaries of these behavior domains and a more integrative team science approach. A more 
integrative approach may be just what is needed to address the public health issue of CVD in 
older women. 
 More generally than just applying this new 24-hour paradigm to CVD research, we need 
to consider that the ideal 24-hour day for optimal heart health, may not be optimal for other 
outcomes, including mental health, cancer prevention, or weight loss. Recently, researchers from 
different international institutions, including myself and representatives from UCSD, attended a 
workshop at the University of Auckland to discuss approaches to 24-hour data. The workshop 
brought together experts in accelerometry, 24-hour measurement, time-use epidemiology 
analysis, and behavioral interventions with the intention of forging a path forward to advance the 
science of 24-hour activity and improve activity behavior guidelines. Results from 24-hour 
compositional analyses are starting to demonstrate that the ideal 24-hour day for the optimal 
cardiometabolic health of women looks very different than the 24-hour day that results in the 
best mental health outcomes for women. The more we employ a 24-hour approach to study 
design, data collection, and interventions the more we will learn that the 24-hour day matters, for 
every health outcome. 
 The 24-hour concept is ideal and will be a challenge to pursue. Currently, there are many 
challenges from data collection to data analysis. For measurement of the 24-hour day, in most 
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cases the location of sensor still depends on the primary outcome behavior. Wrist accelerometers 
are considered the best location for sleep duration and quality,29,30 but data processing methods 
are still under-developed for the assessment of MVPA and SB. The number and popularity of 
consumer wearables may be contributing to the increase in 24-hour data assessment, but may be 
also contributing to the challenges in 24-hour research. As the number of devices being used for 
research continues to increase so does the difficulty in drawing conclusions across studies. In 
addition, compliance over the 24-hour day across multiple days is a challenge and will remain a 
challenge. In this dissertation, of the 6489 women with accelerometer data only 68% of 
participants had valid night wear with >2 nights of data. In addition, best practice for the 
processing of sleep data from sensors still includes large resources, such as visual scoring of the 
data before the application of algorithms. For this dissertation, the visual scoring of each 
participant file took approximately 15 minutes. When this is scaled to large a cohort study, this 
accumulates to a significant amount of person-hours for research teams. At present, that best 
practice data processing techniques are different for PA, SB, and sleep. To be mindful in getting 
the best estimates of each activity and then aggregating the data takes a significant amount of 
work. Further, there is still a gap in the understanding of the best ways to approach 24-hour day 
analysis conceptually. For activities during the waking day we consider a 24-hour day as 12 am 
to 12 am. For sleep, this approach would cut the night of sleep in half. Should the 24-hour day 
then be in-bed time to in-bed time? What if bed time varies greatly within an individual, how do 
we account for that variation? Lastly, while the composition of activity throughout the 24-hour 
day is important, current compositional analysis approaches do not account for patterns in 
activity that have been shown to be related to health, such as breaks in sitting,31 bouts of PA,32 or 
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number of night time awakenings.33 Evidence suggests that these daily patterns in activity are 
uniquely related to health outcomes, and need to be incorporated in future 24-hour research. 
 
 
LIMITATIONS 
 This dissertation is not without limitations. The OPACH cohort, while a rich and unique 
dataset, includes only older women over the age of 63 years who have had no previous incidence 
of CVD, and therefore is not generalizable to the population as a whole. These women make up a 
unique subpopulation who are at increased risk for CVD, but who have also survived (mean age 
of 78.5 years) without experiencing a previous CVD event. It is possible that many of our 
findings are not generalizable to other population groups. Our primary exposure, sleep duration, 
was only assessed at one time point, and therefore we were not able to explore fully the 
relationship between sleep duration and the development of poorer health that some of our 
results suggest. It is possible that many of our findings are based on the current cardiometabolic 
health of women that has developed over time, and one assessment of sleep does not allow for us 
to examine the role that sleep duration played in the development of the poorer cardiometabolic 
health of some women in the cohort. Further, while accelerometry provides better estimates of 
sleep duration than self-report, accelerometers on the hip have shown to provide longer estimates 
of sleep duration when compared to polysomnography and wrist actigraphy.29 Because we 
employed hip accelerometers, valid for total sleep duration only, we were not able to examine 
aspects of sleep quality, beyond self-reported sleep quality. Although unclear, we suspect that the 
compliance issue we had with over 30% of our sample not wearing the device at night may be 
due to the hip location of the accelerometer. Women may have found that the device was 
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difficult to sleep with. The issue with 24-hour compliance in this cohort did significantly limit 
our sample size, which may explain the smaller proportion of short sleepers in our sample, which 
was unexpected. Lastly, sleep disorders, such as obstructive sleep apnea (OSA) was not included 
in our analyses, as they were not assessed in the LLS questionnaire. Previous research suggests 
that sleep disordered breathing and OSA are risk factors for CVD, 34,35 and possible confounders 
in the relationship between sleep duration and CVD.3  
CONCLUSIONS 
 In summary, sleep is essential to well-being. There has been research supporting this fact 
for decades and the evidence continues to grow. This dissertation provides further support that 
sleep duration, measured with an accelerometer, is associated with cardiometabolic health in 
older women. As we continue to examine sleep duration in relation to cardiometabolic health, it 
is important that we do so within the framework of the 24-hour day. To better understand how 
sleep relates to cardiometabolic health, we must better understand the interdependence and 
interrelationships of activities throughout the 24-hour day. Further we need to pay attention to 
short and long sleepers as there is evidence to support that both ends of the U-shaped curve have 
poorer cardiometabolic health. With the increasing prevalence of CVD in the aging population, 
and the need for novel CVD prevention and intervention strategies it is important to consider a 
compositional approach to examining the relationship between the activity throughout the 24-
hour day and cardiometabolic health. Advancing research to consider the composition of the 24-
hour day will better inform the optimal proportion of time spent in sleep, PA, and SB needed for 
optimal cardiovascular health.  
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